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Autoantibodies and autoantigens
1
Differential antibody recognition of the 349-364aa 
B-cell epitope of human La/SSB protein and its 
phosphorylated analogue
AG Terzog lou, JG Routsias, HM M ou tsopou los , AG Tzioufas
Department of Pathophysiology, School of Medicine, University of 
Athens, Athens, Greece
Arthritis Res Ther 2004 6(Suppl 1):1 (DOI 10.1186/ar1043) 
Background La/SSB is a phosphoprotein that associates with various 
small RNA molecules. It has been found that the primary phosphorylation 
site of the molecule during various physiological processes is in Ser366. 
Objectives To determine whether the phosphorylation state of Ser366 
could affect the antigenicity and the recognition of the protein by anti­
bodies from patients with primary Sjogren's syndrome (pSS).
Methods Peptides 349-368aa and phos349-368aa (with the Ser366 
residue phosphorylated) were synthesized. Sera with anti-La specificity 
from 30 patients with pSS and sera from 19 normal individuals were 
examined against the two synthetic peptides in ELISA. The antibody 
specificity against the epitopes was tested with homologous and het­
erologous inhibition assays.
Results Of pSS sera 23% reacted against the 349-368aa peptide. 
Sera binding to unphosphorylated peptide reacted also with 
phos349-368aa. Although the same sera gave a positive reaction 
against both peptides, the optical density values received from antibod­
ies to phos349-368aa were higher, indicating a higher concentration 
or stronger affinity. When phos349-368aa was used as soluble 
inhibitor, in homologous inhibition the reactivity was almost completely 
abolished (92%). In contrast, when the unphosphorylated peptide was 
used as inhibitor, the reactivity of sera against phos349-368aa was 
only partially reduced (35%), indicating that sera from these patients 
possess two distinct groups of antibodies: one against the unphospho- 
rylated and one against the phosphorylated epitope.
Conclusion The phosphorylation of the serine366 residue resulted in a 
significant increase in antibody binding on epitope 349-368aa of 
La/SSB. These observations might explain the increased antigenicity of 
La/SSB autoantigen in various pathological situations in which phos­
phorylation may occur.
2
Surface-bound immune complexes containing 
antibodies to collagen type II induce production of 
TNF-a, IL-1 p and IL-8 from monocytes via FcyRII
M M u lla zeh i1, L M athsson1, J Lam pa2, J R onne lid12
departm ent of Clinical Immunology, Uppsala University, Uppsala, 
Sweden; 2Department of Rheumatology, Karolinska Institute, 
Stockholm, Sweden
Arthritis Res Ther 2004 6(Suppl 1):2 (DOI 10.1186/ar1044) 
Background Antibodies to collagen type II (anti-CII) are found in a sub­
population of rheumatoid arthritis (RA) patients. In joint inflammation CII
epitopes are exposed to anti-CII, with possible formation of surface- 
bound immune complexes (IC). We investigated whether surface- 
bound CII anti-CII IC can induce cytokine production from mononuclear 
cells and the mechanisms behind this.
Methods ELISA plates were coated with native human CII and blocked 
with human serum albumin, after which sera with varying concentra­
tions of anti-CII were added. Serum-free mononuclear cell cultures 
from healthy blood donors were then added, and after 20 hours 
cytokine levels in supernatants were measured using ELISA. Parallel 
wells without cell cultures were developed as anti-CII ELISAs. Sixty-five 
RA patients and 10 control individuals were investigated cross-section­
ally, and 17 patients with anti-CII followed longitudinally for 1 -5  years. 
FcyRII and FcyRIII were blocked with specific antibodies. Cell deple­
tion/enrichment studies were performed to define responder cells. 
High sensitivity CRP measurement was performed with nephelometry. 
Results Surface-bound IC containing CII induce TNF-a, IL-1 P and IL-8 
from mononuclear cells via FcyRII. Cytokine production correlated highly 
with anti-CII levels in the cross-sectional investigation. Five out of the six 
longitudinally followed patients with highest anti-CII levels also showed 
parallel changes in anti-CII OD, cytokine induction and CRP. Deple­
tion/enrichment studies showed monocytes to be the responding cells.
F igu re  1
anti-CII ELISA (OD 405 nm)
Conclusion Surface-bound anti-CII IC can form in inflamed joints. Such 
IC can induce proinflammatory cytokines such as TNF-a, IL-1 p and IL-8 
from monocytes via FcyRII. Most serially followed patients with high anti- 
CII levels showed parallel changes in anti-CII, induced cytokines and 
CRP. This may imply mechanisms of pathophysiological importance in 
the subpopulation of RA patients with high levels of anti-CII.
3
Prothrombin fragment F1+2 in patients with 
antiphospholipid antibodies 
A  A m broz ic , B Bozic, S Cucnik, T Kveder, B Rozm an
University Medical Centre, Department of Rheumatology, Ljubljana, Slovenia 
Arthritis Res Ther 2004 6(Suppl 1):3 (DOI 10.1186/ar1045)
Background Studies of specific markers for in vivo activation of coag­
ulation in patients with antiphospholipid antibodies (aPL) are very rare. S1
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Increased levels of prothrombin fragment F1+2 (F1+2) in patients with 
APS were reported.
Objective Our aim was to ascertain the relationship of F1+2 plasma 
levels with positive anticardiolipin (aCL) and anti-P2-glycoprotein I (anti- 
P2-GPI, and to evaluate the effect of treatment on F1+2 values in 
patients with APS.
Methods A total of 205 samples from 177 patients with suspected or 
confirmed connective tissue disease without APS, and 15 samples 
from nine patients with APS receiving anticoagulant (n =  8) or 
antiplatelet (n =  1) therapy were tested for plasma F1+2 values (Enzyg- 
nost F1+2 micro, Behring, Germany), aCL (IgG, IgM) and anti-P2-GPI 
(IgG, IgM, IgA), all using in-house ELISAs.
Results Elevated values of F1+2 were statistically significantly associ­
ated with medium/high positive results for at least one isotype of aCL 
(P =0 .027), anti-P2-GPI (P = 0 .019 ) and aCL and/or anti-P2-GPI 
(P  = 0 .01 4 ; Table 1). Furthermore, the mean level of F1+2 was signifi­
cantly higher in patients with medium/high aCL or anti-P2-GPI than in 
those with negative/low positive aCL and anti-P2-GPI (P =  0.035). In all 
1 5 plasma samples from APS patients, normal levels of F1+2 were 
measured during treatment.
T a b le  1
A s s o c ia tio n  o f F 1+ 2  w ith  aC L a n d /o r  ß2 -G P I
Normal
F1+2
Elevated
F 1+ 2 Total
aCL and ß2 -GPI negative/low positive 128 (81% ) 
aCL and/or ß2 -GPI medium/high positive 29 (63% )
31 (19% ) 
17 (37% )
159
46
Conclusions Our study showed a significant association of aCL and 
anti-P2-GPI with elevated levels of F1+2 in patients without APS not 
receiving anticoagulant or antiaggregation therapy. aPL are believed to 
be among the important causes of hypercoagulable state in those 
patients. Furthermore, plasma values of F1+2 could be a very useful 
indicator of successful treatment in APS patients.
4
Concomitant appearance of anti-cardiolipin, 
anti-P2-glycoprotein I, anti-prothrombin and 
anti-annexin V antibodies
5  Cucnik, N Gaspersic, T Kveder, B Bozic
University Medical Centre, Department of Rheumatology, Ljubljana, Slovenia
Arthritis Res Ther 2004 6(Suppl 1):4 (DOI 10.1186/ar1046)
Background Anticardiolipin (aCL), anti-P2-glycoprotein I (anti-P2-GPI), 
anti-prothrombin (aPT) and anti-annexin V (aANXV) antibodies are anti­
phospholipid antibodies (aPL) with different antigenic and diagnostic 
specificities.
Objective To ascertain a simultaneous appearance of antigenically 
undefined aCL and antigenically distinct anti-P2-GPI, aPT and aANXV. 
Methods Sera from 92 patients (87 female, five male) were studied 
(63SLE, 19sAPS [SLE with APS] and 10pAPS). IgG, IgM and IgA 
isotypes of aPL were determined using relevant ELISAs.
Results IgG was the most frequently detected isotype in all four ana­
lyzed aPL subtypes. According to diagnostic criteria, aCL were more 
frequently found in patients with pAPS and sAPS than in those with 
SLE. Similarly, aPT were more often elevated in patients with pAPS 
(7/10) and sAPS (6/19) than in SLE (16/63; P <  0.05). The prevalence 
of anti-P2-GPI and aANXV antibodies did not differ between patient 
groups. Regardless of diagnosis, aPT were always detected in combi­
nation with aCL and/or anti-P2-GPI. aPT and aANXV were regularly 
present in the sera positive also for aCL and/or anti-P2-GPI. aANXV 
was detected as a single antibody in only one patient. In the pAPS 
group concurrent multiple aPL varieties (three or four) were signifi- 
S2 cantly more frequently present than one or two types (8/10 versus
2/10; P  <0 .05 ). Statistically significant associations of particular aPL 
with clinical symptoms were as follows: elevated IgG anti-P2-GPI with 
arterial thromboses, thrombocytopenia and foetal loss; IgG aPT with 
arterial thromboses; and IgG aCL with venous thrombosis. IgA isotype 
did not improve the clinical significance of the four analyzed aPL. 
Conclusion In patients with SLE and/or APS, individual aPL were 
found infrequently. Almost half of them had three or more aPL subsets 
elevated at the same time.
5
Antibodies against 25-mer synthetic peptide of M3 
muscarinic acetylcholine receptor 
P Z igon, A  Hocevar, S Cucnik, B Bozic, B Rozman, M Tomsic,
T Kveder
University Medical Centre, Ljubljana, Slovenia 
Arthritis Res Ther 2004 6(Suppl 1):5 (DOI 10.1186/ar1047) 
Background Antibodies against the M3 muscarinic acetylcholine 
receptor (M3R) are believed to have inhibitory effects on parasympa­
thetic neurotransmission in patients with Sjogren's syndrome (SJS), 
leading to lacrimal and salivary glandular dysfunction. The second 
extracellular loop domain of M3R is regarded as the ligand binding site. 
Objectives The aim of our study was to optimize an ELISA for the 
determination of antibodies against M3R synthetic peptide and to 
analyze sera from patients with SJS, patients with systemic lupus ery­
thematosus (SLE) and healthy blood donors.
Methods The M3R 25-mer peptide (KRTVPPGECFIQFLSEPTITFG- 
TAI) was synthesized (Diagen, Ljubjana, Slovenia) and used as the 
antigen for anti-M3R ELISA. Synthetic peptide (10m g/l) was used to 
coat Costar medium binding plates; the detection system was alkaline 
phosphatase/pNPP. Sera from 94 SJS patients (primary and sec­
ondary, age 17 -77  years), 92 SLE patients (age 1 8 -68  years) and 
142 blood donors as controls (age 18 -65  years) were tested.
Results: According to the cutoff value, estimated at the 95 percentile 
of the controls (5/145 pos), positive values for anti-M3R were mea­
sured in 16/95 SJS and 8/92 SLE patients. Statistically significant dif­
ferences in anti-M3R was found in patients with SJS compared with 
blood donors and compared with SLE patients (P = 0 .00 1 2  and 
P  =  0.047, respectively). There was no significant difference between 
SLE patients and controls.
Conclusions This was the first study of anti-M3R antibodies using the 
25-mer synthetic peptide as the antigen on large, well defined groups 
of patients and blood donors, showing highly statistically significant 
elevation in antibodies in primary and secondary SJS compared with 
controls and SLE patients.
6
Association of anti-ribosomal P protein antibodies 
with neuropsychiatric systemic lupus erythematosus 
A  A m broz ic , B Bozic, B Rozm an, B Lestan, T Kveder
University Medical Centre, Department of Rheumatology, Ljubljana, Slovenia 
Arthritis Res Ther 2004 6(Suppl 1):6 (DOI 10.1186/ar1048) 
Background There is an unclear association of anti-P with neuropsy­
chiatric (NP) SLE.
Objective Our objective was to determine the prevalence of anti-P in 
150 SLE patients, focusing on psychosis and/or mood disorders, other 
diffuse NP syndromes and focal NP syndromes, and to analyze the 
manifestation of NP syndromes regarding SLE duration and anti-P 
status.
Methods One hundred and fifty Caucasian SLE patients (133 female, 
17 male) were studied, 88 of whom had a disease duration of more 
than 5 years. IgG anti-P were detected by immunoblotting performed 
on ribosomal extract of HeLa cells and/or by line immunoassay (INNO 
LIA ANA). NP manifestations presenting at any time were defined 
according to ACR case definitions for NP SLE. Patients in whom
Available online http://arthritis-research.c0m/supplements/6/S I
diffuse and focal NP manifestations occurred at the same time were 
classified according to the predominant manifestation.
Results Anti-P were positive in 17/150 (11.3%) patients. Diffuse NP 
manifestations were diagnosed in 9/17 (53%) anti-P positive patients 
(Table 1). Statistically significant associations of anti-P were found with 
(1) psychosis and/or mood disorders (3/11, P <  0.05), (2) other diffuse 
NP syndromes (6/14, P  <0 .0001), and (3) all diffuse NP syndromes 
(9/25; P <0.0001), as compared with patients without diffuse NP 
manifestations (7/92). In the group of 88 patients with disease duration 
greater than 5 years, an even stronger statistically significant associa­
tion of anti-P with diffuse NP manifestations was found.
T a b le  1
S tu d y  fin d in g s
Anti-P positive Anti-P negative
(n = 1 7 ) (n = 1 3 3 )
1 Psychosis and/or mood disorders 3 (18% ) 8 (6%)
2 Other diffuse N P syndromes 6 (35% ) 8 (6%)
3 Only focal N P  syndromes 1 (6%) 32  (24% )
4  Without NP manifestations 1 (41% ) 85  (64% )
Conclusion In our study anti-P antibodies showed a strong association 
with diffuse but not focal NP syndromes in SLE patients, especially 
those with disease duration over 5 years.
7
Human cartilage glycoprotein 39-directed T cell 
responses in health and arthritic diseases 
JHM van B ilsen1, LR Lard1, EIH van der V o o rt1, D E lfe rink2,
A  B akker1, H van D ongen1, A M M  M ilte nb u rg 3, T H u iz inga1, 
R de V ries2, REM Toes1
1Department of Rheumatology, Leiden University Medical Center, 
Leiden, The Netherlands; 2Department of Immunohematology and 
Blood Transfusion, Leiden University Medical Center, Leiden, The 
Netherlands; 3Organon BV, Oss, The Netherlands 
Arthritis Res Ther 2004 6(Suppl 1):7 (DOI 10.1186/ar1049)
Objective Although (self)antigen-directed T cells are thought to be key 
mediators of many autoimmune diseases, a functionally distinct popula­
tion of CD4+ T cells -  T regulatory cells (Treg cells) -  dominantly inhibit 
induction and progression of autoimmunity, as demonstrated in several 
autoimmune models. In humans the presence of Treg cells has been 
shown, but their role in autoimmune disease is not known. Likewise, no 
(auto)antigens recognized by Treg cells have yet been identified at the 
molecular level. The aim of these studies was to gain a better under­
standing of the identity of (auto)antigens recognized by Treg cells. 
Results When analyzing the natural T cell response against a candi­
date autoantigen in rheumatoid arthritis (RA), namely human cartilage 
gp-39 (HC gp-39), we found that healthy donors, although displaying a 
typical Th1 reaction against a mixture of recall antigens, reacted 
against HC gp-39 by producing IL-10. The IL-10 production was medi­
ated by CD4+ T cells. When HC gp-39-directed immunity of RA 
patients was analyzed, a marked contrast was observed as Th 1 -like 
reactivity was observed in a substantial number of patients as deter­
mined by the production of IFN-y. More importantly, we found that HC 
gp-39-directed immunity in healthy donors inhibits the T cell response 
against a mixture of recall antigens. Likewise, HC gp-39-specific immu­
nity as well as HC gp-39-directed, IL-10-producing CD4+ T cell lines 
were able to suppress MHC class I-restricted CTL reactivity. 
Conclusion Together, these data point to a disease-associated bias in 
the type of T cell response against HC gp-39, and identify HC gp-39 
as a naturally occurring autoantigen that is recognized by Treg cells in 
humans.
8
Multiplex analysis of antinuclear antibodies by flow 
cytometry using FIDIS 
PJ Charles
Division of Immunology, Hammersmith Hospitals NHS Trust and
Kennedy Division, Imperial College, London, UK
Arthritis Res Ther 2004 6(Suppl 1):8 (DOI 10.1186/ar1050)
Background FIDIS (BMD, France) is a multiplex analytical flow cytome­
try system for the detection of antibodies. The aim of this study was to 
evaluate the FIDIS connective assay system for the detection of antinu­
clear antibodies (ANA), and to assess the clinical utility of these para­
meters in the diagnosis of connective tissue diseases. The FIDIS 
system simultaneously measures IgG antibodies directed at dsDNA, 
Ro, La, RNP, Sm, Jo-1, Scl-70, rRNP, and CENP-B.
Methods Sera were obtained from 100 patients with SLE and 
100 patients with Sjogren's syndrome. A total of 78 sera from patients 
with rheumatoid arthritis (RA) and 100 from normal healthy blood 
donors were also tested.
Results Antibodies to Scl-70, Jo-1, and rRNP were not detected in any 
of the sera from the disease groups. In the normal control group, the 
only positive result obtained was in one sera that gave a weak positive 
result for anti-CENP-B.
T a b le  1
F req u en cy  o f a n tib o d ie s  d e te c te d  using FIDIS™
SLE SS RA
Anti-Ro 36 69 3.6
Anti-La 13 38 1.2
Anti-Sm 6 0 1.2
Anti-RNP/Sm 37 8 8
Anti-CENP-B 2 2 0
Anti-dsDNA 47 0 3.6
Conclusion The FIDIS connective assay system simultaneously mea­
sures IgG antibodies directed against nine different specificities. The 
data presented indicate that this system provides an alternative strat­
egy for the measurement of specific ANA to the use of multiple single 
analyte assays currently employed in many immunology laboratories.
9
Short-lived plasmablasts and long-lived plasma cells 
contribute to chronic humoral autoimmunity in 
NZB/W mice
BF H oyer1, K M oser1, AE Hauser1, A  P edd inghaus1, C V o ig t1, 
D E ila t2, A  Radbruch1, RA M anz1, F H iepe1
departm ent of Medicine, Rheumatology and Clinical Immunology,
Charité University Hospital and German Rheumatism Research 
Center, Berlin, Germany; 2Department of Medicine, Hadassah 
University Hospital, Jerusalem, Israel
Arthritis Res Ther 2004 6(Suppl 1):9 (DOI 10.1186/ar1051)
The current view holds that chronic autoimmune diseases are driven by 
the continuous activation of autoreactive B and T lymphocytes. 
However, despite the use of potent immunosuppressive drugs 
designed to interfere with this activation, the production of these 
autoantibodies often persists and contributes to progression of the 
immunopathology. In the present study, we analyzed the lifespan of 
(auto)antibody-secreting cells (ASC) in the spleens of NZB/W  mice, a 
murine model of human systemic lupus erythematosus (SLE). The 
number of splenic ASC increased in mice aged 1 -5  months and S3
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became stable thereafter. Less than 60% of the splenic antibody- 
secreting cells were short-lived plasmablasts, whereas 40% were non­
dividing, long-lived plasma cells with a half-life of more than 6 months. 
In NZB/W  mice and D42 immunoglobulin heavy chain ‘knock-in' mice, 
we found that a fraction of DNA-specific plasma cells were also long- 
lived. Although antiproliferative immunosuppressive therapy eliminates 
short-lived plasmablasts, long-lived plasma cells can survive and con­
tinue to produce (auto)antibodies. Thus, long-lived, autoreactive plasma 
cells are a relevant target for researchers aiming to develop curative 
therapies for autoimmune diseases.
Acknow ledgem ent Both senior authors (RAM and FH) contributed 
equally to this work.
10
Immune complexes from RA patients induce FcyRII- 
dependent and RF-correlated TNF-a and IL-8 
production from healthy PBMC
L M athsson1, J Lam pa2, M M u lla zeh i1, J R onne lid12
1Department of Clinical Immunology, Uppsala University, Uppsala, 
Sweden; 2Department of Rheumatology, Karolinska Institute, 
Stockholm, Sweden
Arthritis Res Ther 2004 6(Suppl 1):10 (DOI 10.1186/ar1052)
Background Immune complexes (IC) induce production of cytokines 
from mononuclear cells via Fcy-receptors. We investigated whether 
polyethylene glycol (PEG)-precipitated IC from serum and synovial fluid 
(SF) from rheumatoid arthritis (RA) patients can induce production of 
proinflammatory cytokines.
Methods In one study we compared sera and SF from 15 RA patients 
and 15 healthy control sera. In a second study we used paired sera 
and SF from 32 RA patients, 66% of which were rheumatoid factor 
(RF) positive. The precipitates where diluted to the original volume in 
PBS before 10% were added to serum-free PBMC cultures from two 
healthy blood donors. After 20 hours TNF-a and IL-8 levels were mea­
sured using ELISA. In separate cell culture experiments FcyRII and 
FcyRIII were blocked. RF in serum was determined by nephelometry 
and IgG levels in precipitates were measured using ELISA.
Results We found a correlation between TNF-a induced by PEG pre­
cipitates from RA SF and RF levels in sera. Using the normal ELISA, 
PEG precipitates were shown to contain some TNF-a but no IL-8, 
using both whole and F(ab')2 anti-TNF-a antibody ELISA systems. 
TNF-a levels induced by SF precipitates, but not by serum precipitates, 
correlated with number of swollen and tender joints at the time of sam­
pling. Blockade of FcyRII partly inhibited the TNF-a production in cul­
tures stimulated with precipitated IC, whereas blockade of FcyRIII did 
not show any inhibitory effects.
F igu re  1
to 10 Spearm an's  rho = +0.481  
P =  0 .0 0 8 5  0
O
o
o o o o  o 
O O O ©  O  QD
30  300
T N F  -a  production (pg/ml) from  healthy donor 
P B M C  stimulated with RA S F  precipitates
Conclusion We showed a link between RF, PEG precipitated IgG 
levels, and the induction of TNF-a and IL-8 from RA PEG precipitates. 
The stimulation is partly mediated via FcyRII. As precipitate-induced 
cytokine levels correlate with the number of affected joints, these find­
ings supports the hypothesis that IC and the correlated RF production
S4 have a direct link to cytokine dependent inflammation in RA.
11
Differential regulation of the expression of 
chemokine receptor 3 and 4 during plasma cell 
differentiation
G M ueh linghaus1, L C ig lia n o 1, H Leyendeckers2, S A rce3, 
A  R adbruch1, RA M anz1
1Deutsches Rheuma Forschungszentrum, Berlin, Germany; 2Miltenyi 
Biotec, Bergisch Gladbach, Germany; 3Mucosal Immunity University 
Buffalo, Buffalo, USA
Arthritis Res Ther 2004 6(Suppl 1):11 (DOI 10.1186/ar1053)
The duration of specific antibody titers ranges from a few weeks up to 
several years. While the formation of antibody secreting plasma cells 
takes place in secondary lymphoid tissues, long-lasting antibody 
responses are provided by bone marrow plasma cells. The majority of 
plasma cells initially formed remains in secondary lymphoid tissues and 
die within a few days. Plasma cells that migrate into the bone marrow 
or into chronically inflamed tissues can survive for much longer periods 
of time. The capacity of plasma blasts to migrate into these tissues is 
regulated by chemokine receptors. Expression of CXCR4 is important 
for plasma cell migration into the bone marrow. CXCR3 ligands 
expressed in large quantities in chronically inflamed tissues (e.g. in 
effected kidneys in systemic lupus erythematosus) and can attract plas­
mablasts, thus mediating plasma cell accumulation at those sites. Here 
we analyzed the regulation of chemokine receptor expression during 
plasma cell differentiation in culture. Purified CXCR3-negative B cells 
were activated T dependently in a two-step culture system, for 3 days 
by CD40 ligand together with IL-2 and IL-10 and for 5 more days with 
IL-2 and IL-10. Alternatively, cells were stimulated T independently with 
CpG, IL-2 and IL-10. Addition of IFN-y or monocyte/T-cell culture 
supernatant in the initial culture, but not at late stages, induced the 
expression of CXCR3 on plasma cells, thus suggesting that the regula­
tion of this receptor is an early event during plasma cell differentiation. 
In contrast, CXCR4 was present on all plasma cells, formed under any 
stimulation conditions and even when CXCR4-negative B cells were 
activated to form plasma cells. These data indicate that expression of 
CXCR4 and, as a consequence, the potential to migrate into the bone 
marrow is generally associated with differentiation into plasma cells, 
whereas the expression of CXCR3 must be induced by the inflamma­
tory cytokine IFN-y.
12
Two B cell populations differentially expressing IgVH 
mRNAs in human RA synovium
S R uzickova1, O K rystu fkova1, L Sedova1, J N iederlova1, 
Z  C im burek2, T D orner3, J Vencovsky1
institu te  of Rheumatology and LGE, Prague, Czech Republic; 
2Department of Immunology and Gnotobiology, CAS, Prague, Czech 
Republic; 3Department of Rheumatology, Charité, Berlin, Germany
Arthritis Res Ther 2004 6(Suppl 1):12 (DOI 10.1186/ar1054) 
Background The lymphocytic infiltrates sometimes organized in 
ectopic germinal centres in rheumatoid arthritis (RA) synovium contain 
locally activated B cells expressing hypermutated immunoglobulin tran­
scripts and recombination-activating genes (Rag), suggesting an 
ongoing antigen driven process directly in synovium.
Objective To test this hypothesis, mutational frequencies of 
immunoglobulin mRNAs, signs of isotype switching and Rag gene 
expression in individual RA synovial B cells were analyzed.
Methods Single-cell RT-PCR was used to analyze individual synovial 
CD19+CD38+ and CD19+IgM+ B cells (as the reference population) 
from two RA patients.
Results We found significantly reduced frequencies of peripheral 
blood CD19+CD38+ B cells from RA patients as compared with con­
trols, suggesting their possible migration into the site of inflammation. 
Three subsets of CD19+CD38+ B cells in RA synovium were detected, 
expressing (1) only IgM transcripts (IgM+, 13.5%), (2) only IgG tran­
scripts (IgG+, 48.7%), and (3) both IgM and IgG mRNAs (IgM+IgG+, 
37.8%). The differences in mutational frequencies between them were 
significant (Table 1). Over 40% of analyzed cells coexpressed Rag 
mRNAs. Similar subsets and expression patterns were found in 
CD19+IgM+ B cells; however, IgG+ cells displayed significantly 
decreased mutational frequencies (3.6%; P <0.0001). This might 
reflect the presence of synovial B cell populations that differ in their 
maturational status or biological function.
T a b le  1
M u ta tio n a l fre q u e n c ie s  o f  IgVH  m R N A s in RA syn ovia l C D 19+C D 38+ and  
C D 19+ IgM + p o p u la tio n s
C D 19+ C D 3 8+  C D 19+IgM +
IgM+ IgM+IgG+ +G IgM+ IgM +IgG + +GIg
Total of nt 1761 66 1 7 46 8 3 212 8 2570 2079
Mutated nt 94 46 5 4 6 2 75 110 75
M F (%) 5.3 7.0 9.9 3.5 4.3 3.6
13
Immunomics in inflammatory rheumatic diseases
Z K on thu r1, K A d o lp h 2, G B urguera1, A  S te rn ja k12, A  F örs te r2, 
H Lehrach1, GR B urm ester2, K S k rin e r12
1Max-Planck-Institut für Molekulare Genetik, Berlin, Germany; 
2Rheumatology & Clinical Immunology, Charité, Berlin, Germany
Arthritis Res Ther 2004 6(Suppl 1):13 (DOI 10.1186/ar1055) 
Autoimmune diseases such as rheumatoid arthritis (RA) are character­
ized by autoantibodies to different autoantigenic proteins. Using pro- 
teomic 2D immunoblots, we identified a new 40 kDa autoantigen -  
hnRNP A3 -  from HeLa nuclear extracts, which is frequently (30%) 
detected by RA. Moreover, we used a set of protein arrays of about 
50 000 proteins derived from a human foetal brain cDNA expression 
library for screening with patient sera. Additionally, we utilized a human 
foetal brain cDNA library in a robot-based T7 phage display screening 
system with RA patient sera. To determine the diversity of the enriched 
library, we amplified the cDNA inserts and hybridized them onto the 
custom-made human ENSEMBL cDNA array. By these methods, over 
80 clones were identified to bind patient immunoglobulins. Moreover, 
nine clones show only IgA-specific reactivity. We have now evaluated 
two different clones thoroughly: the carboxyl-terminal half of the nucleo­
lar phosphoprotein p130 (NOPP 130) and a clone representing a 
41-amino-acid mimetic peptide showing homology to calreticulin, a 
previously reported autoantigen. The remaining proteins are still under­
going thorough investigation. Applying state-of-the-art proteomic tech­
niques, such as protein array and phage display, we have succeeded in 
identifying more than 80 potentially autoantigenic marker molecules, of 
which we have characterized a subset for RA specificity by screening 
with large numbers of patient and control sera. However, none of the 
molecules characterized thus far is exclusively discriminatory for RA 
and they all exhibit overlap with other autoimmune diseases.
Available online http://arthritis-research.com/supplements/67S1
Autoantibodies: anticitrullin antibodies
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VIDAS-EDRA fully automated testing of 
autoantibodies to citrullinated proteins for the 
diagnosis of rheumatoid arthritis
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Antiperinuclear factor and antikeratin antibodies (AKA) were shown to 
belong to the same family of rheumatoid arthritis (RA)-specific autoanti­
bodies directed at ‘citrullinated' peptidic epitopes borne by (pro)filag- 
grins. We showed that their major target in the synovial tissue of RA 
patients is deiminated (citrullinated) fibrin. Although (pro)filaggrins are 
probably only cross-reactive proteins, their in vitro detection allowed 
the development of several highly efficient tests for the diagnosis of 
RA. Among those, the CCP ELISAs (CCP1 and CCP2), based on a 
cyclic citrullinated peptide derived from human filaggrin, and the ArFA- 
ELISA that we developed using a citrullinated recombinant rat filaggrin 
appear to be the most promising. The rapidly growing interest of 
rheumatologists in autoantibodies to citrullinated proteins rendered the 
development of a convenient, fully automated test the next challenge. 
Based on the ArFA-ELISA, we developed an automated test on the 
VIDAS machine (bioMérieux), called VIDAS-EDRA (early diagnosis 
rheumatoid arthritis). Thresholds were defined on a large series of 
617 patients with well defined, established rheumatic diseases, includ­
ing 181 patients with RA. Antibodies to CCP1 and CCP2 
(Immunoscan, Eurodiagnostica) were sought following the manufac­
turer procedures. Rheumatoid factor (RF) and AKA were also analyzed 
in the series. The diagnostic performances of the tests were compared. 
In established diseases the diagnostic sensitivity of the VIDAS-EDRA 
was found to be identical to that of CCP2, and was significantly higher 
than tests for AKA, CCP1 and RF.
Autoantibodies to citrullinated proteins can be efficiently detected with 
the highly specific and sensitive automated test VIDAS-EDRA.
T a b le  1
D ia g n o s tic  s e n s itiv ity  (% ) co m p u ted  a t  th re s h o ld s  a llo w in g  95 .2%  and  
9 8 .6 %  d ia g n o s tic  sp e c ific ity  to  b e  ach ieved
95 .2 %  specificity 9 8 .6 %  specificity
AKA 51.4 42 .5
RF 56.4 16
CCP1 65.7 56 .9
C C P 2 74 63.5
VIDAS-EDRA 71.8 63.5
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deiminase enzymes
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Background Autoantibodies to citrullinated proteins (anti-CCP) can be 
detected in up to 80% of rheumatoid arthritis (RA) patients with very
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high specificity (98%). Citrulline residues, the target of the anti-CCP anti­
bodies, are formed by post-translational modification of arginine residues, 
catalyzed by peptidylarginine deiminase enzymes (PAD; EC 3.5.3.15). 
Objective Our aim was to investigate the full complexity of the family of 
PAD enzymes and to locate putatively important conserved residues or 
domains.
Methods We performed a thorough query for PAD sequences using 
EST and genomic databases. With these data we constructed a com­
plete PAD alignment (ClustalW) and a phylogenetic tree (Treeview), 
and mapped the different genes.
Results Next to the previously described PADs, we found several 
(partial) novel sequences, both mammalian and nonmammalian. From 
the alignment (available online at http://www.interscience.wiley.com/ 
jpages/0265-9247/suppm at/2003/25/v25.1106.html), it is clear that 
the carboxyl-terminal half is more conserved than the amino-terminal 
part. Some of the fully conserved residues (His475 and Cys655) have 
been suggested to be important for catalytic activity of murine PAD2. 
These residues would fit in the ‘catalytic pocket', as has been 
described for other arginine converting enzymes (arginine deiminases 
EC 3.5.3.6. and amidinotransferases EC 2.1.4.1.). The negative charge 
(on average -1 4 ) and low pI (about 5.8) of the enzyme are important 
for its interactions with arginine substrates and with Ca2+ ions, which 
are essential for PAD activity. A phylogenetic tree confirmed the human 
PAD5 to be the orthologue of the murine PAD4. By comparing mRNA 
and genomic sequences, the individual exons of all murine and human 
PADs could be mapped in a tight conserved gene cluster (human chro­
mosome 1p36.1; mouse #4E1; rat #5q36). Structural characterization 
of PADs will yield valuable clues regarding the aetiology of RA and for 
the development of PAD inhibiting drugs.
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Background Rheumatoid factor (RF) is found in patients with systemic 
lupus erythematosus (SLE). Anti-citrullinated peptide antibodies 
(ACPA) are more specific for rheumatoid arthritis than RF.
Objective Our aim was to determine the prevalence of RF and ACPA 
in SLE patients.
Methods In this study, samples from 201 consecutive patients diag­
nosed with SLE and fulfilling ACR criteria were used. Fine ANA reactiv­
ities were tested by INNO-LIA™ANA (Innogenetics, Gent, Belgium) and 
by IIF on C. luciliae. RF was detected by latex fixation. ACPA were 
detected by anti-CCP2 ELISA (Euro-Diagnostica, Arnhem, The Nether­
lands) and by a research INNO-LIA™RA (Innogenetics, Gent, Belgium) 
for the detection of anti-pepA and anti-pepB antibodies. The preva­
lences of ACPA were compared by the McNemar test.
Results RF at a titre > 160 was found in 26 patients (13.0%). ACPA 
were found in 16 samples (Table 1). The prevalence of anti-CCP2 anti­
bodies was significantly higher than that of anti-pepA antibodies 
(P =  0.001) and anti-pepB antibodies (P =0.022).
Conclusion RF is found in 13.0% of SLE patients. Anti-CCP2 antibod­
ies are false-positive in 7.0% (n = 1 4 )  of SLE patients, which occurs 
significantly more often than anti-pepA (1.5%, n =  3) and anti-pepB 
S6 (2.5%, n =  5) antibodies.
T a b le  1
C h arac te ris tics  o f A C P A -p o s itiv e  S LE p a tie n ts
Anti-C CP2
RF (U/ml; cut-off ANA fine
(titre) 25  U/ml) Anti-pepA Anti-pepB reactivities
1 1280 186 + + Ro60, SSB
2 0 28 - - SmB, SmD, histones, 
dsDNA
3 6 40 9 - + RNP-C
4 0 168 - - dsDNA
5 0 53 - - SmB, dsDNA
6 80 2 - + Histones, dsDNA
7 0 76 SmB, RNP-A, 
RNP-C, RiboP, 
histones
8 40 64 SmD, SmB, 
RNP-70k, 
RNP-C, RiboP
9 0 58 - - -
10 3 2 0 110 SmB, RNP-70k, 
RNP-A, RNP-C, 
Histones, dsDNA
11 0 28 - - -
12 0 36 - - -
13 3 2 0 78 + + SmB, RNP-70k, 
RNP-A, RNP-C
14 80 56 - - RNP-A, RiboP, 
Histones
15 6 40 52 - - RNP-70k, RNP-A
16 3 2 0 1600 + + Ro60
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Background Rheumatoid factor (RF) is the classical serum marker for 
rheumatoid arthritis (RA). Anti-citrullinated peptide antibodies (ACPA) 
have a higher sensitivity and specificity (spec) for RA.
Objective Our aim was to evaluate the diagnostic and predictive value 
for RA of RF and antibodies to pepA and pepB (two synthetic sub­
strates for ACPA detection) in a setting relevant to routine clinical 
practice.
Methods In this prospective multicentre study, samples were collected 
at academic and nonacademic centres from 1003 consecutive patients 
presenting for diagnostic work-up when the clinician included RA in the 
differential diagnosis. RF was detected by latex fixation. A research 
INNO-LIA™RA (Innogenetics, Belgium) was used to detect anti-pepA 
and anti-pepB antibodies. Diagnoses were made by the clinician using 
ACR criteria after 1 year follow-up. ROC curve analysis was used to 
evaluate the diagnostic performance of the tests.
Available online http://arthritis-research.com/supplements/6/S1
F igu re  1
1 -  Specificity
ROC curves.
Results The following diagnoses were made: definite RA (n =144 ), 
non-RA (n =  629), undifferentiated (n =  156), and lost to follow up 
(n =  74). The first two groups were used to determine sensitivity, speci­
ficity, and positive predictive value (PPV). ROC curve analysis (Fig. 1) 
showed a higher area under the curve for RF than for anti-pepA and 
anti-pepB antibodies (0.839 versus 0.784 and 0.788, respectively), but 
in the high specificity region anti-pepA and anti-pepB antibodies per­
formed better than RF (Table 1).
T a b le  1
D ia g n o s tic  p erfo rm a n c e  o f  seru m  m a rk e rs  using d iffe re n t cu t o ffs
Antibody Cutoff Sensitivity (%) Specificity (%) PPV (%)
PepA Low 63.6 9G.6 6G.7
PepB 64.3 9G.G 59.G
RF 69.2 90.1 61.5
PepA Intermediate 62.9 95.1 74.4
PepB 61.5 95.1 73.3
RF 55.2 94.6 69.9
PepA High 5B.7 98.1 B7.5
PepB 4B.3 98.1 B5.2
RF 42.G 97.B 81.1
PepA Very high 41.3 99.G 9G.B
PepB 37.1 99.G B9.B
RF 21.0 99.G B3.3
Conclusion When high specificity is required, anti-pepA and anti-pepB 
antibodies have a markedly higher sensitivity than RF. The highest PPV 
are found when ACPA are very high.
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Background Autoantibodies (Ab) directed against citrulline (Cit)-con- 
taining proteins have a specificity of nearly 100% in rheumatoid arthritis
(RA) patients. The presence of these markers early in disease, even 
before clinical onset, and the observation that these autoantibodies are 
produced locally in the pannus suggest an involvement in the patho­
genesis. The targeted epitopes are generated by deimination, a post- 
translational modification catalyzed by the enzyme peptidyl arginine 
deiminase.
Objective Our aim was to analyze the presence of Cit-proteins and fib­
rinogen in the joints at different time points in collagen-induced arthritis 
(CIA) in rats and to investigate how citrullination of an autoantigen 
affects its immunogenicity.
Methods Synovial tissue sections from DA rats were stained for 
expression of citrulline and fibrinogen. Lew1AV1 rats were immunized 
with Cit-rat serum albumin (RSA) or unmodified RSA, and antibody and 
T-cell responses were evaluated.
Results Citrulline was detected in arthritic joints from disease onset 
and increased expression was noted as disease progressed into a 
more chronic state. Naive rats or time points before arthritis onset were 
negative for citrulline-specific staining. Infiltrating cells, as well as the 
cartilage surface, stained positive for citrulline, although the major 
source of citrullinated proteins appeared to be fibrin depositions. A 
specific Cit-RSA T-cell response was observed in animals challenged 
by Cit-RSA. In contrast, no response was recorded when RSA was 
used as a stimulus. The IgG response revealed not only a response 
toward the modified protein but also cross-reactivity to the unmodified 
form of RSA.
Conclusion In CIA, joint inflammation precedes the presence of Cit- 
proteins and citrullination increases immunogenicity of an autoantigen.
Our results suggest that citrullination is induced by inflammation and 
might be contributing to the development of autoreactive T and B cells.
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peptides
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Background Antifilaggrin antibodies are highly specific serological 
markers of rheumatoid arthritis (RA). They have been shown to com­
prise a heterogeneous population of antibodies directed at citrullinated 
peptides. Recent studies suggest that the site of the initial antigenic 
trigger where these autoantibodies are produced can be localized to 
the synovial tissue.
Objective The aim of this study was to compare the recognition pat­
terns of antibodies in paired serum and synovial fluid samples of RA 
patients toward citrullinated peptide sequences to investigate whether 
or not they comprise the same antibody population.
Methods Arginine-rich peptide sequence corresponding to human pro- 
filaggrin (amino acid residues 306-324) and sequences with citrulline 
substitution at different positions were synthesized by mutipin peptide 
synthesis on solid support. Completely citrullinated variant of the 
1 9-mer peptide and shortened sequences were also produced. The 
reactivity of these peptides with paired sera and synovial fluid samples 
of RA patients were determined (n =  25). Results were evaluated sta­
tistically using the paired t test.
Results and Conclusion The results (Table 1) show that the 
12 -19  amino acid long epitopes are recognized by homogeneous anti­
body population present in serum and synovial fluid, whereas the reac­
tivities toward short citrullinated sequences differs significantly. 
Acknow ledgem ent This work was supported by the Hungarian grant:
OTKA T037876. S7
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T a b le  1
C o m p ariso n  o f th e  reac tiv itie s  o f  a n tib o d ie s  in p a ired  seru m  and  
syn ovia l f lu id  sam p le s
Sequence P  value Sequence P  value
S H Q E S T X G X S X G X S G X S G S 0.754 TX G R S R G R S G R S G 0.598
S H Q E S T X G X S X G X S G R S G S 0.382 TX G R S R G R S G R S 0.129
S H Q E S T X G X S X G R S G R S G S 0.09 T X G R S R G R S G R 0.04*
S H Q E S T R G X S X G X S G X S G S 0.081 T X G R S R G R S G 0.122
S H Q E S T R G R S X G X S G X S G S 0.143 T X G R S R G R S 0.128
S H Q E S T R G R S R G X S G X S G S 0.192 TX G R S R G R 0 .039*
TX G R SR G 0 .019*
TX G R SR 0 .003*
TX G R S 0 .003*
TX G R 0 .011*
^Significant difference. X, citrulline.
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Background Autoantibodies to deiminated (citrullinated) forms of the 
a  and P chains of fibrin (AhFibA), also known as antifilaggrin autoanti­
bodies (AFA), are the most specific serological markers of rheumatoid 
arthritis (RA). Deimination is critical in generating the AhFibA epitopes 
and, in the synovial tissue (ST), deiminated fibrin is their major antigenic 
target. Existence of fibrin deimination specifically in RA patients could 
explain why the AhFibA response is RA specific.
Methods and Results To explore such an association, the presence of 
deiminated fibrin in the ST was assessed in a series of 32 patients, 13 
with RA and 19 with non-RA rheumatological disorders (controls). ST 
biopsies were collected in macroscopically inflamed areas identified 
under needle arthroscopy of the knee. Histopathological examination 
confirmed the existence of synovitis in all of the samples. The presence 
of deiminated fibrin was first assessed by immunoblotting of ST 
extracts using antibodies to citrullyl residues and to the a  and P chains 
of fibrin, and AhFibA purified from a pool of RA sera. Deiminated fibrin 
was evidenced in all of the ST samples. Moreover, variations in the ratio 
of deiminated to total fibrin were not related to diagnosis. Immunohisto- 
chemical analysis, performed on adjacent synovial biopsy sections of
19 of the 32 patients, using antibodies to the P chain of fibrin and to 
citrullyl residues, allowed us to confirm the results obtained by 
immunoblotting, because deiminated fibrin was detected in six RA 
patients and six controls.
Conclusion Our results show the presence of deiminated fibrin in the 
ST is not specific for RA and suggest that it is induced by ST inflam­
mation. Moreover, they show the production of AhFibA is not a direct 
consequence of the presence of deiminated fibrin in the ST. Nonethe­
less, AhFibA are tightly associated with RA. Because they are also 
present very early in the disease course, linked to disease severity and 
produced in the ST, they probably play an important role in RA patho- 
S8 physiology.
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Background Antibodies directed at the Sa antigen are highly specific 
for rheumatoid arthritis (RA) and can be detected in approximately 40% 
of RA sera. The antigen, a doublet of protein bands of about 50 kDa, is 
present in placenta and in RA synovial tissue. Although it has been 
suggested that the Sa antigen is identical to citrullinated vimentin, 
experimental proof for this has never been published.
Objective In this study we investigated the precise nature of the Sa antigen. 
Methods Freshly purified Sa antigen from placenta was analyzed by 
mass spectrometry. Immunoprecipitation and Western blot studies 
were performed with anti-Sa patient sera, anti-vimentin antibodies and 
antibodies specifically recognizing citrullinated proteins.
Results and Conclusion Peptide sequences that were obtained from 
highly purified Sa antigen were unique to vimentin. Recombinant 
vimentin, however, was not recognized by anti-Sa reference sera. In 
vivo, vimentin is subjected to various post-translational modifications, 
including citrullination. Because antibodies to citrullinated proteins are 
known to be highly specific for RA, it was investigated whether Sa was 
citrullinated. Our data show that Sa indeed is citrullinated vimentin. 
Anti-Sa antibodies thus belong to the growing family of anti-citrullinated 
protein antibodies, which also includes the well described anti-filaggrin 
and anti-CCP antibodies. The presence of the Sa antigen in RA syn­
ovial tissue, the observations that vimentin is citrullinated in dying 
human macrophages and that citrullinated vimentin peptides are prefer­
entially presented by HLA-DR4/shared epitope, make Sa a unique 
autoantigen in RA. Studies on Sa may provide new insights on the 
potential role of citrullinated synovial antigens and the antibodies 
directed at them in the pathophysiology of RA.
Cytokines and chemokines
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Elevated expression of IL-18 in Sjogren’s syndrome: 
distinct expression patterns of the active and 
proactive forms
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Background IL-18 is an important immunoregulatory and proinflamma- 
tory cytokine that is produced by various cell types, including antigen- 
presenting cells and epithelial cells. IL-18 is synthesized as a 
biologically inactive precursor molecule (proactive IL-18) that converts 
into an active, mature molecule after enzymatic cleavage. Upregulated 
levels of IL-18 have been identified in several autoimmune diseases, 
but its role in Sjogren's syndrome (SS) is uncertain.
Objective The aim of the study was to investigate the role of IL-18 in SS. 
Methods RT-PCR analysis, immunohistochemistry and immunoblotting 
(with distinct anti-IL-18 antibodies against the proactive and active 
forms) were applied for the detection of IL-18 in cultured SG epithelial 
cell (SGEC) lines established from patients with SS (n =  5) and from 
non-SS disease control patients (n =  5), as well as in minor SG biopsy 
specimens obtained from patients with primary SS (n =  12), secondary
SS (n =  5) and non-SS disease controls (n = 7 )  were used.
Available online http://arthritis-research.c0m/supplements/6/S I
Results The expression of IL-18 mRNA was detected in all SGEC lines 
tested. In addition, cultured SGEC express constitutively the proactive, 
but not the mature, form of IL-18 protein, as demonstrated by 
immunoblotting. In minor SG biopsies, strong expression of the IL-18 
proactive protein was detected in the ductal epithelial and CD68+ infil­
trating macrophages of the SS patients, but not in the controls. The 
expression of the active form of IL-18 was detected only in SS patients 
and mainly in those with extended inflammatory lesions. In these 
samples, active IL-18-positive cells were observed exclusively among 
the CD68+ macrophages of the mononuclear cell infiltrates. 
Conclusion Our data possibly indicate the role of IL-18 in the expan­
sion of lymphoepithelial lesions of SS patients. SGEC were found to 
express only the proactive form of IL-18, the biological significance of 
which remains to be determined.
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with autoantibody levels and nephritis
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Background In the NZB/W  murine model of lupus, various studies 
have analyzed cytokine production during disease development with 
contradictory results.
Objective The aim of this study was to analyze cytokine pattern of 
splenic T cells from NZB/W  mice. We assessed the possibility that a 
shift in cytokine production is associated with age, disease activity, or 
manifestation of nephritis.
M ethods NZB/W  mice of different ages spanning 5 -3 6  weeks were 
analyzed, and healthy (BALB/c x  NZW) F1 mice were used as controls. 
Proteinuria was measured using albustix. Plasma creatinine and autoan­
tibody levels were detected by commercial test kid and by ELISA, 
respectively. Splenic CD4+ T cells stimulated with PMA/Ionomycin were 
analyzed for intracellular cytokine staining by FACS analysis.
Results The increased frequency of IFN-y producing CD4+ T cells corre­
lated with age, anti-dsDNA IgG antibody levels and proteinuria. The 
increasing number of IL-10 producers was only associated with anti­
dsDNA antibody levels and proteinuria. A small gain in IL-4+ T cells corre­
lated with plasma creatinine. Neither the number of IL-10 nor that of IL-4 
exhibiting T cells correlated with age. There was no significant change 
observed in the production of TNF-a. Calculating the IFN-y/IL-4 ratio, an 
increasing shift toward a Th1 response was observed. The shift strongly 
correlated with anti-dsDNA antibody titres and proteinuria. In contrast, no 
cytokine shift could be observed in control mice with increasing age.
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Background Osteoprotegerin (OPG) is a soluble decoy receptor that 
acts as a receptor antagonist, blocking OPG ligand (OPGL) induced 
osteoclastogenesis. In vitro, proinflammatory cytokines such as tumour 
necrosis factor (TNF) upregulate endothelial OPG expression. 
However, low levels of endothelial OPG expression are seen in synovial 
biopsies from patients with active rheumatoid arthritis (RA) associated 
with high levels of TNF. In order to elucidate the in vivo interaction 
between TNF and the OPG/OPGL system in RA, we investigated the 
effect of anti-TNF therapy on synovial expression of OPG and OPGL.
Methods OPG, OPGL and CD31 were evaluated by immunohisto- 
chemistry in serial synovial biopsies obtained from 20 RA patients 
before and after 8 weeks of treatment with Etanercept (Amgen and 
Wyeth Pharmaceuticals, USA) or Infliximab (Schering-Plough, Stock­
holm, Sweden). Biopsies were evaluated by double-blind semiquantita­
tive analysis and image analysis. Statistical analysis was performed 
using the Wilcoxon's signed-rank test followed by Bonferroni correc­
tions for multiple comparisons.
Results OPG was expressed in all studied synovial biopsies, mainly in the 
CD31-positive endothelial cells. OPGL expression was detected in syn­
ovial areas rich in T cells, with low expression in endothelial cells and 
macrophages. Treatment with Infliximab significantly increased synovial 
OPG expression whereas the increase in synovial OPG expression 
observed after Etanercept treatment did not reach statistical significance.
Neither infliximab nor etanercept influenced OPGL expression following 
8 weeks of treatment. The ratio between synovial OPGL and OPG expres­
sion decreased following treatment with infliximab (P <  0.05, after Bonfer- 
roni comparisons) and etanercept (NS after Bonferroni correction).
Conclusion Our findings suggest a particular OPG-TNF interaction in 
vivo as well as a potential difference in action between the two anti- 
TNF agents tested.
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with psoriatic arthritis and rheumatoid arthritis 
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Background and Objective IL-20 is a novel cytokine that is involved in 
skin inflammation, in part by serving as an autocrine factor for ker- 
atinocytes. The aim of this study was to investigate the expression of 
IL-20 in the inflamed synovium of patients with psoriatic arthritis (PsA) 
and rheumatoid arthritis (RA) to provide more insight into the possible 
role of this cytokine in inflammatory joint disease. To further assess the 
regulation of IL-20 expression, in vitro experiments were conducted to 
determine the effects of IL-1 P and TNF-a on the expression of IL-20 by 
RA fibroblast-like synoviocytes (FLS).
Methods Synovial biopsy specimens of patients with PsA (n = 1 1 )  and 
RA (n = 1 0 )  were obtained from actively inflamed joints by needle 
arthroscopy. Immunohistologic analysis was performed using a mono­
clonal antibody (mAb) specific for IL-20. In addition, we measured 
IL-20 expression in RA FLS in the presence or absence of 250 pg/ml 
IL-1 P and 100 ng/ml TNF-a by immunocytochemistry.
Results IL-20 was expressed in the intimal lining layer, in the synovial 
sublining and on endothelium in both PsA and RA patients. Digital 
microscopic analysis of synovial tissue revealed clear IL-20 expression 
with comparable overall scores in both patient groups (RA 
149775 ±  56466, PsA 123862 ± 5 0 6 3 0  [mean integrated optical 
density ±  SEM]; NS). The in vitro experiments revealed marked induc­
tion of IL-20 after stimulation with IL-1 P and TNF-a in RA FLS.
Conclusion IL-20 expression is induced in FLS by proinflammatory 
cytokines, including TNF-a and IL-1 p. In addition, IL-20 is markedly 
expressed in psoriatic skin lesions, but also in the synovium of patients with 
PsA and RA, suggesting a role in various forms of inflammatory joint disease.
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Cross-talk between TRAIL and TGF-P in regulation of 
collagen production in scleroderma lung disease 
VV Y urovsky
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Background Tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) is a TNF family member, which has been closely associated with S9
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regulation of the immune response and pathogenesis of autoimmune 
diseases. The expression of TRAIL was found in CD8 T cells that had 
undergone oligoclonal expansion in the lungs of patients with systemic 
sclerosis (scleroderma) and were able to stimulate collagen production 
in lung fibroblasts in vitro. Among the family members, TRAIL displays 
highest homology to Fas ligand, the receptor of which may mediate not 
only cell apoptosis but also the proliferation of normal human fibroblasts. 
Objective Considering structural and functional similarities between 
TRAIL and Fas ligand, we examined the effects of soluble multimerized 
TRAIL on normal human lung fibroblasts.
Methods and Results TRAIL at doses in excess of 100 ng/ml induced 
apoptotic death of fibroblasts. However, at lower concentrations it was 
found to stimulate collagen production. Collagen alpha2(I) mRNA 
expression was assessed by real-time RT-PCR; and total soluble colla­
gen was measured in culture supernatants using the Sircol assay. Both 
alpha2(I) collagen mRNA and total soluble collagen were increased 
upon TRAIL stimulation, with peak response (more than fourfold 
increase in mRNA) at 1 ng/ml TRAIL. DNA microarray analysis revealed 
TRAIL-induced increase in the expression of a number of genes 
involved in tissue remodeling, including those related to the transform­
ing growth factor (TGF)-p pathway. The microarray results were con­
firmed by Northern blot analysis of TGF-p, mRNA expression and by 
measurements of total active TGF-p, in culture supernatants. In addi­
tion, antibody-mediated blocking of TGF-p was shown to abrogate 
TRAIL-induced collagen synthesis.
Conclusion These data suggest that TRAIL can enhance extracellular 
matrix production in fibroblasts by triggering TGF-p expression, which 
acts in an autocrine manner. If this process continues uncontrolled, it 
may contribute to the development of fibrosis, particularly in the lungs 
of patients with scleroderma.
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Effects of reduced ATP-formation on cytokine 
production and proliferation in human peripheral 
CD4+ T cells
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Background and Objective The function of immune cells is dependent 
upon a constant and adequate supply of energy (ATP), which is mainly 
formed by oxidative phosphorylation (OXPHOS). In arthritis, microenvi­
ronmental conditions are characterized by low levels of oxygen and 
glucose. Thus, effector cells of the innate immune system are recruited 
to sites where they face an acute need to respond to these demanding 
conditions. We investigated how immune cells maintain viability and 
function under these circumstances, and which immune processes are 
limited to what extent by energy deficiency.
Methods From peripheral mononuclear cells obtained from healthy 
donors, we isolated CD4+ T-cells (MACS, > 9 8%  purity) and incubated 
them (37°C, 5% CO2) in RPMI 1640 with 11.1 mmol/l glucose (permits 
OXPHOS and glycolysis) and without glucose (permits OXPHOS only). 
As a measure of oxidative ATP formation, cellular oxygen consumption 
was determined amperometrically with a Clark electrode. Under the 
conditions of unaffected ATP production and ATP production inhibited 
stepwise using myxothiazole, PMA/ionomycin-stimulated cytokine pro­
duction (IL-2, IL-4, IFN-y, TNF-a, 6 hours) and anti-CD3-/anti-CD28- 
stimulated proliferation (over 96 hours) were quantified.
Results In the glucose-containing medium, both stimulated cytokine 
production and proliferation were unaffected, even under complete 
suppression of OXPHOS. Only when OXPHOS and glycolysis were 
suppressed simultaneously and almost completely were cytokine pro­
duction and proliferation significantly decreased.
Conclusions We have quantified the energy requirement of specific 
immune functions in human CD4+ T cells. Under maximally inhibited 
S10 OXPHOS, glycolysis fully compensates for the ATP supply for the energy
requirements of the immune functions investigated. These data demon­
strate a high adaptive potential of CD4+ T cells to maintain specific 
immune functions even under massively impaired energetic conditions.
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HMGB1 but not IL-1 expression in chronic arthritis 
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Objective In this study we examined the effect of glucocorticosteroids 
(GCs) in chronic arthritis on IL-1 a, IL-1 P, TNF and the newly discov­
ered proinflammatory cytokine HMGB1, which was previously thought 
of only as a DNA-binding protein.
Methods Seventeen chronic inflammatory arthritis patients with 
swelling and pain in at least one large joint were chosen. Synovial biop­
sies were sampled by arthroscopy before and 9 -1 2  days after intra- 
articular injection of 40 mg triamcinolone hexacetonide. Synovial 
membrane T cells (CD3), macrophages (CD68, CD163), as well as the 
proinflammatory cytokines IL-1 a, IL-1 P, TNF and HMGB1 were studied 
by immunohistochemistry followed by semiquantitative analysis and/or 
digital image analysis.
Results All investigated joints had clinical signs of active arthritis with 
swelling and pain of the joint before treatment, which was reduced in 
all joints after treatment. Numbers of T cells were reduced whereas 
numbers of macrophages were not significantly changed. Expression of 
HMGB1 was significantly reduced, whereas no significant effects were 
seen on the expression of IL-1 a, IL-1 P or TNF. Before treatment 
HMGB1 staining was mainly extracellular and cytoplasmic in the 
mononuclear inflammatory follicles and lining layer, whereas endothelial 
cells of scattered capillaries, arterioles and venules had a primarily 
cytoplasmic staining. After treatment staining pattern was more promi­
nent in the nucleus and reduced extracellularly.
Conclusions Proinflammatory cytokines in chronic arthritis are affected 
differently by intra-articular GCs. The marked reduction in HMGB1 
expression and the lack of significant change in IL-1 and TNF thus indi­
cate that GCs may exert their in vivo effects in arthritis via partly differ­
ent pathways than in previous in vitro experiments.
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Human adipose tissue: an important novel source of 
IL-1Ra
J-M Dayer, C M eier
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The increased production of proinflammatory IL-1, TNF-a and IL-6 is 
part of the pathogenesis of various immunoinflammatory diseases, often 
accompanied by metabolic and cardiovascular complications. Cachexia 
and obesity have been shown to accompany these diseases, and the 
cytokines IL-1, TNF-a, IL-6 are said to be increased in white adipose 
tissue (WAT). Few studies have been conducted to examine counter­
regulatory mechanisms of cytokine inhibitors. Sera of obese patients 
showed a more than sevenfold increase in IL-1Ra, which matches levels 
present in inflammatory autoimmune diseases and sepsis, and corre­
lates with body mass index and insulin resistance. Subcutaneous and 
visceral human WAT of obese patients contained 0.4 and 0.7 ng of 
IL-1Ra/mg protein, respectively. Thus, in an obese individual weighing 
120 kg with 50% body fat, total WAT is estimated to contain 0.6 mg 
IL-1Ra protein (i.e. 200 times the amount of IL-1Ra in total serum), thus 
representing one of the main sources of IL-1 Ra production. The
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increased IL-1Ra expression -  not associated with an increase in IL-1P 
-  argues for an anti-inflammatory, compensating mechanism associated 
with obesity. Our experiments with human WAT explants showed a 
strong stimulatory effect of PMA and, more importantly, of IFN-p (as 
much as 5- to 10-fold). Because the latter is a fibroblast-derived IFN, it 
is tempting to speculate that stromal cells and adipocytes might be part 
of a paracrine mechanism that regulates IL-1Ra secretion. In fact, newly 
formed adipose tissue is often found close to inflammatory lesions (i.e. 
synovial tissue). The functional consequences of the increased produc­
tion of IL-1Ra by adipose tissue may represent an important counter­
regulatory mechanism to inflammation at the local level. Furthermore, 
IL-1RI and IL-1 IL-1RAcP were also expressed in human WAT. Thus, 
substances that increase the production ratio of IL-1 Ra/IL-1P by 
adipose tissue might serve as a novel target for therapeutic strategies in 
human immunoinflammatory diseases.
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IL-1-dependent cartilage damage in a macrophage- 
driven arthritis model can be circumvented by T cell 
IL-17
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Background In the murine macrophage-mediated SCW-induced 
arthritis, IL-1 plays a dominant role in cartilage destruction, as was 
shown in previous studies using cytokine gene knockout mice or anti­
bodies against IL-1. T cell IL-17 is a proinflammatory cytokine that has 
many IL-1-like activities. IL-17 is expressed in the synovium of RA 
patients and may play a role in rheumatoid arthritis (RA) pathology. 
Objective In the present study we examined the potency of T cell IL-17 
to bypass the relative IL-1 dependency of cartilage damage during 
macrophage-driven SCW-induced arthritis.
Methods SCW-arthritis was induced in IL-1 deficient mice and their 
C57Bl/6 controls by intra-articular injection of 25 |ig  SC W  fragments. 
Sixteen hours before the induction of arthritis, an adenoviral vector 
expressing murine IL-17 or a control virus was injected into the knee 
joint. Total knee joints were isolated for histological analysis of joint 
inflammation by H&E staining and cartilage damage was measured as 
proteoglycan (PG) depletion by Safranin O staining.
Results During SCW-induced arthritis, cartilage damage was clearly 
suppressed in IL-1 deficient mice. Overexpression of T cell IL-17 in the 
SC W  arthritis model caused aggravation of the synovial inflammation 
and induces more severe PG depletion. IL-1-/- mice showed the same 
influx of inflammatory cells and comparable degree of cartilage damage
F igu re  1
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PG depletion 10 days after induction of SC W  arthritis, in combination 
with the ia injection of control virus or AdIL-17.
as control mice (Fig. 1), indicating that overexpression of IL-17 causes 
loss of IL-1 dependency in this model.
Discussion These data show circumvention of the IL-1 dependency of 
cartilage damage by T cell IL-17 in the macrophage-driven SC W  arthri­
tis model. IL-1 and its receptor share the same signaling pathway 
through TRAF-6 and NF-k B as IL-17. These data suggest that T cell 
IL-17 can replace the catabolic function of IL-1 regarding cartilage 
damage, directly or via interplay with other macrophage-driven factors.
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IL-13 overexpression during immune complex 
arthritis diminishes MMP-mediated VDIPEN 
expression
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Background We recently found that overexpression of the Th1 
cytokine IFN-y during immune complex arthritis (ICA) resulted in deteri­
oration of matrix metalloproteinase (MMP)-mediated VDIPEN expres­
sion. On the contrary, overexpression of a Th2 cytokine might protect 
against cartilage destruction.
Objective The aim of the study was to investigate whether local overex­
pression of the Th2 cytokine IL13 by gene transfer is able to diminish 
MMP-mediated VDIPEN expression during ICA and, if so, what mecha­
nism is involved.
Methods Human IL-13 (hIL-13) was locally overexpressed in the knee 
joint using an adenovirus (AdhIL13) and hIL-13 was detected in syn­
ovial washouts after 1, 2, 3, and 7 days. ICA was induced in C57Bl/6 
by ia injection of lysozyme-antilysozyme complexes 1 day after 
AdhIL13 injection. Histology and synovium specimens were taken at 
days 1, 3 and 7 after ICA onset. Joint inflammation and MMP-mediated 
VDIPEN expression were determined. mRNA levels of MMP-3, 
MMP-12, and MMP-13 were detected in the synovium by Q-PCR. 
Results AdhIL13 injected in naïve knee joints results in 1000pg/m l 
hIL-13 after 1 day, and increased to 3000 pg/ml detected at days 2, 3 
and 7. Surprisingly, IL-13 did not diminish joint inflammation, because 
the influx of inflammatory cells was similar in the Addel70 and AdhIL13 
group. MMP-mediated VDIPEN expression was not found 1 day after 
ICA onset because of the early time point. At day 3, IL-13 overexpres­
sion resulted in a twofold reduction in VDIPEN expression and a three­
fold reduction at day 7, compared with the control group. This 
decrease might be the result of a declined production of MMPs. 
However, the mRNA level of MMP-3 was comparable between the two 
groups, whereas MMP-12 and MMP-13 mRNA levels were three times 
higher in the IL-13 group.
Conclusion IL-13 overexpression during ICA does not alter the inflam­
matory response. VDIPEN expression was decreased, but this was not 
reflected by declined MMP production, suggesting that IL-13 interferes 
at the level of activation of pro-MMPs.
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Objective To study the role of TNF in sacroiliitis using a TNF-a trans­
genic (hTNFtg) mouse model. S11
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Methods hTNFtg mice were divided into two groups receiving either 
phosphate-buffered saline (PBS) or anti-TNF (infliximab). Wild-type 
mice served as negative control. Treatment was initiated at week 4 and 
continued over 6 weeks. Thereafter the sacroiliic joints were histologi­
cally assessed for joints inflammation, local bone erosion and cartilage 
destruction.
Results. All hTNFtg mice showed a severe bilateral sacroiliitis. Treat­
ment of hTNFtg mice with anti-TNF, however, resulted in a significant 
(P <  0.05), over 80% reduction in sacroiliacal inflammation. Further­
more, in hTNFtg mice severe erosions of the iliac as well as sacral sub­
chondral bones were detectable, whereas treatment with anti-TNF 
virtually abrogated local bone erosions indicated by a reduction by over 
99%. In addition, application of anti-TNF also significantly (P < 0 .05 ) 
reduced the numbers of osteoclasts at the front of erosions by 98% 
compared with PBS-treated hTNFtg mice. The amount of sacroiliac 
cartilage of hTNFtg mice was significantly (P < 0 .05 ) reduced by 73% 
compared with anti-TNF treated mice.
Conclusion These data clearly indicate that TNF overexpression 
causes bilateral, erosive sacroiliitis and that anti-TNF therapy is a suit­
able tool with which to treat this condition.
Major histocompatibility complex
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Background HnRNP-A2 (RA33) is a multifunctional RNA-binding 
protein involved in various aspects of post-transcriptional regulation of 
gene expression. Autoantibodies to A2/RA33 are present in approxi­
mately 30% of rheumatoid arthritis (RA) patients whereas autoreactive 
T cells have been found in almost 60% of the patients.
Objective The aim of the study was to analyze the T cell response to 
A2/RA33 and its possible involvement in the pathogenesis of RA. 
Methods The Tepitope programme as well as ELISAs were used to 
define peptide sequences within A2/RA33 that may bind to the RA 
associated MHC molecules HLA-DR*0401 and DR*0404. Candidate 
peptides were analyzed in vivo by immunizing DR*0401 transgenic (tg) 
mice and restimulating lymph node cells or purified CD4+ or CD8+ 
T cells with the peptides. The potential of A2/RA33 to induce disease 
was studied by immunizing arthritis-prone DBA/1 mice, a strain bearing 
the DR*0401 transgene on the DBA/1 background and TNF tg mice 
(which spontaneously develop erosive arthritis).
Results Immunogenic sequences were found clustered in the RNA 
binding domains of A2/RA33. In immunized HLA-DR4 tg mice the 
reaction to A2/RA33 peptides seemed to be entirely produced by 
CD4+ T cells showing a Th1 phenotype, with some of the peptides 
inducing high production of IFN-y. However, immunization of HLA-DR4 
tg or DBA/1 mice with A2/RA33 protein induced only mild swellings in 
some animals with no pathological findings in the histological analysis. 
On the other hand, immunization of TNF tg mice enhanced arthritis sig­
nificantly. These mice overexpressed A2/RA33 in the joint, whereas 
expression was very low in wild-type mice.
Conclusion A2/RA33 derived peptides can bind to RA associated 
HLA class II molecules and induce a proinflammmatory Th1 response. 
The increased arthritis observed in immunized TNF tg mice suggests 
that the autoimmune response to A2/RA33 may indeed be involved in 
the pathogenesis of RA by inducing or enhancing disease in a proin- 
S12 flammatory environment.
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affects severity of rheumatoid arthritis
FA van Gaalen, J van A ken, TWJ H uiz inga, GMTh Schreuder, 
FC Breedveld, E Zane lli, WJ van V enroo ij, CL Verw eij, 
RRP de Vries, REM Toes
Department of Rheumatology, LUMC, Leiden, The Netherlands 
Arthritis Res Ther 2004 6(Suppl 1):34 (DOI 10.1186/ar1076) 
Objective The role of HLA class II molecules in the pathogenesis of 
rheumatoid arthritis (RA) is unclear. HLA class II molecules are involved 
in the interaction between T and B lymphocytes required for long-lived 
B-cell responses and generation of high-affinity IgG antibodies. The 
relationship between HLA class II polymorphisms and RA-specific IgG 
anti-cyclic citrullinated peptide (CCP) antibodies was investigated. 
Methods High-resolution HLA-DR and DQ typing and anti-CCP2 anti­
body testing was performed in 279 RA patients from the Leiden Early 
Arthritis cohort. The presence of anti-CCP antibodies was analyzed in 
carriers of the different DR and DQ alleles. Disease progression was 
measured over a period of 4 years by scoring radiographs of hands and 
feet using the Sharp/Van der Heijde method.
Results Carriers of DQ-DR genotypes containing proposed RA sus­
ceptibility alleles were significantly more frequently anti-CCP antibody 
positive. Carriership of one or two HLA-DRB1 shared epitope (SE) 
alleles was significantly associated with production of anti-CCP anti­
bodies (OR 2.9, 95% CI 1.6-5.2 and OR 10.2, 95% CI 3.8-28.5, 
respectively). In SE carrying, anti-CCP antibody positive patients an 
increased rate of joint destruction was observed (mean Sharp score 
7.6 points/year) compared with non-SE carrying, anti-CCP positive 
(2.4 points; P  =  0.03), SE carrying, anti-CCP-negative patients 
(1.6 points; P < 0 .00 1 ) and non-SE carrying, anti-CCP negative 
patients (1.6 points; P <  0.001).
Conclusions Anti-CCP antibodies are associated with HLA class II RA 
susceptibility alleles and presence of both factors is indicative of a 
severe disease course. As the principal role of HLA class II molecules 
is antigen presentation to T cells, these data point toward a pivotal role 
of citrulline-directed T cells in the production of anti-CCP antibodies.
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N de V ries1, H T ijssen2, PLCM van R ie l3, LBA van de P u tte3,
PP Tak1
d iv is io n  of Clinical Immunology and Rheumatology F4-218, 
AMC/University of Amsterdam, Amsterdam, The Netherlands; 2Blood 
Transfusion and Transplantation Immunology; 3Rheumatology, UMC St 
Radboud, Nijmegen, The Netherlands
Arthritis Res Ther 2004 6(Suppl 1):35 (DOI 10.1186/ar1077) 
Objective and Methods Antigenic peptides anchor by amino acid 
residues to pockets within the antigen-binding groove of the HLA- 
DRB1 molecule. In order to assess whether a pocket-wise analysis of 
HLA-encoded susceptibility might provide a better fit to the immuno- 
genetic data in rheumatoid arthritis (RA) than the shared epitope 
hypothesis, HLA-DRB1 typing findings in 167 patients with recent 
onset RA and in 166 controls were analyzed.
Results The shared epitope (residues 67 -74 ) borders pockets 4 and 
7. After stratification for pocket 4, polymorphisms in pocket 7 did not 
influence RA risk. However, after stratification for pocket 7, both substi­
tutions in the a  helix bordering pocket 4 and substitutions at position 
13 in the floor of this pocket independently and significantly influenced 
RA risk. Furthermore, substitutions at position 86 in pocket 1 also had 
an effect on RA risk. Pairs of HLA-DRB1 alleles that only differ in the 
glycine/valine dimorphism showed a consistent tendency toward 
increased risk for the glycine variant in a pooled analysis (pooled OR
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1.66; p1 =  0.08). This observation is also strongly supported by data 
from previous publications.
Conclusion Structural data indicate that HLA disease association may 
be determined by the make-up of individual pockets within the antigen- 
binding groove of the HLA molecule. In RA, susceptibility is influenced 
by genetic polymorphisms in pocket 4 of the HLA-DRB1 molecule, 
both in the floor of this pocket and in the a  helix bordering this pocket. 
In addition, genetic variation in pocket 1 modifies RA risk.
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Objective HLA-DRB1 alleles encoding the shared epitope (SE) are 
associated with rheumatoid arthritis (RA) but the underlying biological 
mechanism is unknown. Several case-control studies have been pub­
lished on the protective effect of particular SE negative alleles, accord­
ing to the physicochemical properties of the fourth antigenic peptide 
binding pocket (P4). The present study was undertaken to test those 
hypotheses taking advantage of a familial based association analysis. 
Methods One hundred French Caucasian families with one RA patient 
and both parents were genotyped for HLA-DRB1. The analysis relied 
on the allelic frequency calculation, the transmission disequilibrium test 
(TDT) and the genotype relative risk analysis (GRR).
Results After the demonstration of the association of SE with RA in our 
sample (P =  4.8 x  1 0-14), we replicated the strong protective effect of 
HLA-DRB1*1501 alleles (P = 4 .7 7  x  10-7). We also replicated a pro­
tective effect against RA of the alleles with an isoleucine at position 67 
(P =  1.93 x  1 0-5) and the alleles with an aspartic acid at position 70 
(P =  3 x  10-3). We failed to replicate any protective effect of the alleles 
with a neutral or negative electric charge of the P4 pocket, nor a modu­
lation of SE effect by those alleles. We also failed to replicate the pro­
tective effect of Q and De alleles according to the functional 
categorization of HLA-DRB1 alleles.
Conclusion Our findings are in keeping with a protective effect against 
RA of SE negative alleles (HLA-DRB1*1501, alleles with an isoleucine 
at position 67 and alleles with an aspartic acid at position 70).
T-cells
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Background CD4+ T cells lacking the costimulatory molecule CD28 
have been described in both elderly individuals and in several chronic 
inflammatory disorders, one being rheumatoid arthritis (RA).
Objective We characterized such CD28nullCD4+ T cells from RA 
patients in order to identify surface markers correlating with function. 
Methods Peripheral blood mononuclear cells were analyzed for 
surface marker expression by flow cytometry and in vitro cultures were 
set up for functional studies.
Results One-third of the RA patients had a persistent and expanded 
CD28null population, which comprised up to half of the CD4+ T cells in 
peripheral blood. Functionally, CD28nullCD4+ T cells were potent 
effector memory cells with regard to their proliferation and cytokine 
secretion profiles. This functional capacity correlated with a hitherto 
unpublished surface phenotype, the cells being uniformly CCR7-nega- 
tive and CD43high. In addition, we re-evaluated previously suggested 
cell surface markers, and found CD57 and CD11b expressed on the 
majority of these NKT-like CD4+ T cells. When combining phenotypic 
and functional analyses of subpopulations of the CD28nullCD4+ 
T cells a new terminally differentiated T cell population was identified. 
Conclusion We believe that in the balanced immune system of healthy 
individuals, CD28nullCD4+ T cells are under homeostatic control, 
whereas in an unbalanced immune system such as in autoimmune 
disease CD28nullCD4+ T cells are allowed to expand and have the 
capacity to enhance ongoing inflammatory reactions.
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Background All organisms contain naturally occurring haptens in the 
form of enzyme cofactors bound covalently to apoproteins. One 
example is flavine adenine dinucleotide (FAD). Autoantibodies recog­
nizing flavoproteins, with specificity for flavin or flavin-peptide were 
described in patients with myocarditis or other muscular diseases. 
Objective We wanted to test the hypothesis that FAD-peptide reactive 
T cells exist in patients with acute myocarditis.
Methods Peripheral blood mononuclear cells (PBMNC) were tested in 
vitro with a purified FAD-peptide (from a trypsin digested, affinity puri­
fied flavoprotein) or a synthetic peptide with the same amino acid 
sequence. Proliferation was measured by 3H-TdR incorporation, and 
the secretion of IFN-y by ELISA.
Results PBMNC from four patients with acute myocarditis showed 
positive responses to the FAD-peptide, in contrast to control individu­
als. The synthetic FAD-free peptide did not induce a response. 
Conclusions The results are consistent with the hypothesis that during 
the inflammation of the heart cardiomyocytes liberate normally cryptic 
mitochondrial FAD-peptides, which induce a T cell response. Similar 
mechanisms could be envisaged in inflammatory diseases of other 
compartments (e.g. the joints in rheumatic diseases [1]). 
Acknow ledgem ent Supported by grants of the DFG.
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Background Shigella flexneri is one of the bacteria causing reactive 
arthritis (ReA). However, no target antigen for the cellular and humoral 
immune response against Shigella is yet known.
Methods Shigella were grown in culture followed by differential cen­
trifugation, after which a cytoplasmic and the 70S ribosomal fraction 
were obtained. By means of density gradient centrifugation the 70S 
ribosome was divided into its two subunits, the small ribosomal subunit 
30S and the large ribosomal subunit 50S. The proteins derived from 
both subunits were further separated by FPLC-ion exchange chro­
matography. Mononuclear cells from synovial fluid of 3 HLA-B27 posi­
tive patients with Shigella-induced ReA were stimulated with whole 
Shigella, the cytoplasmic fraction, the ribosomal subunits and with 
single protein fractions from the ribosomal subunits gained by FPLC. 
Stimulatory protein fractions were subsequently cleaned by RP-HPLC 
and identified by stamp-size 2D PAGE.
Results Seventeen protein fractions from the 30S subunit and 
23 protein fractions from the 50S subunit were obtained. A lymphocyte 
proliferation was seen after stimulation with whole Shigella, with the 
cytoplasmic fraction and the two ribosomal subunits but not with control 
antigens. More interestingly, five single ribosomal proteins out of 40 
were equally stimulatory in all three patients, indicating that they repre­
sent immunodominant T cell antigens. Characterization by 2D PAGE 
identified the ribosomal proteins L15, L18, L21, L22 and L23 from 50S 
(‘L' for large subunit) and S3 from the 30S (‘S' for small subunit). 
Conclusion This approach allows the identification of T-cell epitopes 
derived from bacteria in ReA patients. In a first step we identified pro­
teins from the highly conserved ribosomal fraction of Shigella flexneri. 
Their role in the pathogenesis must be further investigated.
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Background Naturally occurring CD4+CD25+ T cells have been 
shown to suppress immune responses both in vivo and in vitro. Finding 
a way to harness their regulatory abilities is of particular value in both 
transplantation and autoimmunity, where unwanted immune reactions 
need to be eliminated. Tantalizing evidence for their future potential is 
demonstrated by their ability to cure T cell mediated colitis induced in 
SCID mice [1]. However, many autoimmune diseases display a strong 
humoral component, such as rheumatoid arthritis. It is unknown 
whether CD4+CD25+ T cells are effective in these B cell-mediated 
autoimmune diseases.
Objective We tested the ability of CD4+CD25+ T cells to modulate 
collagen-induced arthritis (CIA), a disease dependent on the presence 
of B cells [2].
Methods In order to determine the role of endogenous CD25+ T cells 
in CIA, CD25+ cells were first depleted in mice before immunizations to 
induce CIA. The therapeutic value of these cells was assessed by 
adoptively transferring preactivated CD4+CD25+ T cells into mice 
S14 during the onset of disease.
Results Depletion of CD25+ cells before CIA induction lead to a has­
tened severe disease in comparison with nondepleted control mice. If 
CD4+CD25+ T cells were transferred to mice therapeutically, the mice 
had a significantly milder disease.
Conclusion CD4+CD25+ T cells can treat chronic arthritis and proba­
bly have the potential to treat a wide spectrum of autoimmune dis­
eases, including those that are mainly mediated by B cells.
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Background Lupus nephritis is one of the hallmarks of systemic lupus 
erythematosus (SLE). Although there is increasing evidence that these 
T lymphocytes might play a major role in the initiation and maintenance 
of nephritis, there is hardly any functional data about these cells. 
Objective The aim of the present study was to characterize kindey infil­
trating T cells with respect to their activation state, their memory/effector 
phenotype, proliferation, and cytokine production. Furthermore, the ability 
to provide T cell help for the generation of autoantibodies was tested. 
Methods CD4+ T cells derived from inflamed kidney tissues of 7- to 
9-month-old NZB/W  F1 mice were analyzed for the expression of 
CD69, CD25, CD28, CD62L, CD45RB, CD44, and CD71 by FACS. 
Furthermore, intracellular cytokine staining was measured after 
PMA/Ionomycin stimulation, and the ability of kidney T cells to respond 
to the SmD1 83-119 peptide with increased generation of anti-dsDNA 
antibodies was tested by ELISPOT.
Results and Conclusion The kidney infiltrating CD4+ T cells were highly 
activated in terms of CD69 expression (28%). The expression of CD25 
was lower compared with splenic T cells (8.6% versus 15.2%). The 
CD4+ T cells were mainly of the effector/memory phenotype (55-60%), 
but there was also a high frequency of naïve T cells (40-45%).There was 
a low frequency of proliferating T cells (5%), as detected by CD71 
expression. Most T cells were of the Th1 phenotype and produce proin- 
flammatory cytokines such as IFN-y (16.8%) and TNF-a (11.8%). Kidney 
T cells give no help for the generation of anti-dsDNA antibodies.
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Background CD25+CD4+ regulatory T cells participate in the regula­
tion of immune responses. We recently demonstrated an enrichment of 
CD25brightCD4+ T cells with a capacity to control T cell proliferation 
in the joints of patients with rheumatoid arthritis (RA).
Objective Here, we extend these studies to investigate a possible 
accumulation of regulatory T cells in the joints of other inflammatory dis­
eases, and their potential to suppress cytokine production in patients 
with rheumatic diseases, including RA.
Available online http://arthritis-research.c0m/supplements/6/S I
M ethods Synovial fluid and peripheral blood samples were 
obtained during relapse from 204 patients with spondy­
loarthropathies, juvenile chronic arthritis, and RA, and the frequency 
of CD25brightCD4+ T cells was determined. For functional studies, 
synovial cells from six patients were sorted by flow cytometry and 
the suppressive capacity of these CD25brightCD4+ T cells was 
determined in in vitro coculture.
Results O f 204 patients, 198 patients exhibited a higher frequency 
of CD25brightCD4+ T cells in synovial fluid as compared with 
peripheral blood. Additionally, in comparison with healthy individuals, 
the patients had significantly fewer CD25brightCD4+ T cells in 
peripheral blood. Functionally, the CD25brightCD4+ T cells sup­
pressed both type 1 and 2 cytokine production, and proliferation, 
independent of diagnosis.
Conclusion Irrespective of diagnosis of the inflammatory joint disease, 
an accumulation of CD25brightCD4+ T cells in the joint and reduced 
numbers in peripheral blood suggest an active recruitment of regulatory 
T cells to the affected joint. Their capacity to suppress both prolifera­
tion and cytokine secretion might contribute to dampen the local 
inflammatory processes.
Dendritic cells
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Background Dendritic cells (DCs) are the professional antigen-pre­
senting cells that produce a large set of chemokines. Recent evidence 
suggests that DCs, by their production of chemokines, are important in 
the inflammatory cascade.
Objective The aim of the study was to evaluate the expression of 
chemokines by DCs and synovial tissue from patients with RA in com­
parison with that from healthy individuals.
Methods Immature and mature DCs were obtained using standardized 
protocols as described previously. The expression of the chemokines 
DC-CK1, ELC, IL-8, MIP-1a, SDF-1a, SDF-1a, lymphotactin, SLC, 
MIP-3a, TARC and MDC in iDCs, mDCS and synovial tissue was 
determined by using real-time quantitative RT-PCR techniques 
(PRISM).
Results iDCs of RA patients (n =  10) express low levels of ELC and 
MIP-1a, and high levels of MDC and TARC, which were equal when 
compared with DCs from healthy individuals (n =  8). However, the 
expression of DC-CK1 (P < 0 .001 ) and IL-8 (P = 0 .02 ) by iDCs from 
RA patients was significantly higher. After full maturation, expressions 
of DC-CK1 (P <0.001), ELC (P <0.001), IL-8 (P =0 .02), MIP-1a 
(P < 0 .001 ) and TARC (P < 0 .001 ) were significantly higher in DCs 
from RA patients relative to healthy donors. In RA synovial tissue, 
DC-CK1 (230-fold), ELC (400-fold) and IL-8 (36-fold) were expressed 
at much higher levels when compared with healthy individuals. TARC 
was also expressed at higher levels in RA synovial tissue but this failed 
to achieve significance.
Conclusion In DCs both from patients with RA and in biopsies of 
rheumatoid synovium, significantly higher levels of DC-CK1, ELC and 
IL-8 mRNA are present relative to their normal counterparts. MIP-1a 
and TARC were expressed at higher levels exclusively by DCs from RA. 
These results suggest that DC-CK1, ELC, MIP-1a and TARC, along 
with DCs, play a critical role in RA.
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Objective We studied the immune response against pcDNA3.1 in a 
model of rheumatoid arthritis (RA), namely collagen-induced arthritis 
(CIA), to understand the role of innate immunity in RA and the inocuity 
of this empty plasmid used in gene therapy.
Methods CIA was induced in DBA/1 mice by type II collagen sc injec­
tions. At D10 and D24 after immunization, 1 |ig  pcDNA3.1neo (CpG 
islets-containing plasmid) or pCor (control plasmid) were injected in 
lower limbs. DBA/1 BMDC were stimulated in vitro with 
pcDNA3.1neo, pCor, LPS+/- TNF for 24 and 48 hours. BMDC were 
analyzed in flow cytometry, and IL-1 2, TNF-a, IFN-y and IL-10 were 
tested by ELISA in BMDC supernatants. BMDC endocytosis capacity 
and MLR functional capacity were also studied. CIA was treated with a 
stimulated dendritic cell population after immunization.
Results PcDNA3 decreases the incidence of arthritis in collagen 
immunized DBA mice. Stimulation of BMDC with pcDNA3 increased 
costimulation molecule expression, cytokine production (IL-12, TNF-a,
IFN-y and IL-10), and allogeneic T cell proliferation, but at a lower level 
than LPS stimulation. Moreover, pc DNA3 stimulated BMDC have 
higher endocytosis capacity than LPS stimulated BMDC. Treatment of 
collagen immunized mice with this steady-state activated-dendritic cell 
population decreases the incidence of arthritis.
Conclusion We demonstrated that the stimulation of dendritic cells 
with an empty plasmid, pcDNA3.1neo, could lead to a steady state of 
activation that could support tolerance induction. This effect needs to 
be further characterized and seems to be a ‘yes' or ‘no' answer, as inci­
dence is decreased but total clinical scores are not statistically modi­
fied. Histological studies will help to understand this mechanism.
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Background The RANK/RANKL pathway is critical in osteoclastogene- 
sis and bone destruction, and is implicated in focal bone erosion in 
rheumatoid arthritis (RA). Because deficient mice show major lymph 
node (LN) abnormalities, here we looked at its involvement in the 
immune response during chronic inflammation.
Methods W e investigated, by immunohistochemistry, RANK and 
RANKL expression by DC and T cell subsets in paired RA synovium- 
LN and also in normal peripheral blood mononuclear cells (PBMC) 
stimulated with PMA/PHA.
Results In RA synovium, RANKL+ cells were detected in the lining 
layer and the lymphocytic infiltrates whereas RANK expression was 
restricted to the perivascular infiltrates. In LN, RANK+ and RANKL+ 
cells were diffusely expressed in both T-cell zone and germinal centres.
Double staining with anti-RANK or anti-RANKL and anti-CD1a or anti- 
DC-LAMP antibodies revealed that, in paired RA synovium-LN sec­
tions, some immature CD1a+ DC express RANK and RANKL whereas 
some mature DC-LAMP+ DC expressed only RANK. Double staining 
with the CD3, CD4 T-cell markers and the IFN-y and IL-17 Th1 cell 
markers showed that some of CD3+, CD4+, IFN-y+ and IL-1 7+ cells 
expressed RANKL, whereas none of them expressed RANK. The same S15
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pattern was observed on activated PBMC. The RANK+ cells, detected 
in unstimulated PBMC, were identified as CD14+ monocytes. 
Conclusion This study showed the involvement of RANK/RANKL in 
DC-T cell interactions occurring during the inflammatory process. In 
particular, RANK expression appears to be limited to the sites of 
immune reaction both in synovium and LN.
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Background Rheumatoid arthritis (RA) is an autoimmune disease that 
is characterized by chronic inflammation of the joints leading to 
destruction of cartilage and bone. RA is characterized by synovial lining 
hyperplasia and chronic infiltration by T and B cells, 
monocyte/macrophages, dendritic cells (DC) and other cells. DC are 
the only antigen-presenting cells that can prime naïve Th cells and initi­
ate immune responses. In peripheral blood two major DC subsets can 
be found: BDCA1+CD11c+CD123low (myeloid), with the ability to 
produce IL-12; and BDCA4+CD11c- CD123high (plasmacytoid), 
which produce large amounts of type I interferons (IFN-a/p).
Objectives To gain insight into the in vivo characteristics of DC, we 
investigated the distribution of BDCA1+ and BDCA4+ DC in RA 
patients compared with healthy controls and non-RA patients.
Methods The frequencies of BDCA1+ and BDCA4+ DC in peripheral 
blood and synovial fluid were analyzed by FACS analysis. Immunohisto- 
chemistry was performed in synovial tissue from RA patients to get 
more insight into the distribution of these two DC subsets in vivo. 
Results We found that the frequencies of both BDCA1 + and BDCA4+ 
DC in peripheral blood of RA patients are decreased compared with 
healthy controls and non-RA patients. Although the frequencies of both 
DC subsets in synovial fluid from RA patients were increased com­
pared with peripheral blood, they did not differ significantly from non- 
RA patients. In rheumatoid synovial tissue, both DC subsets were 
localized close to CD3 and CD8 T cell infiltrates.
Conclusion BDCA1+ and BDCA4+ DC are preferentially localized in 
the synovium of RA patients, where they could stimulate memory 
T cells and sustain the inflammatory process. Conceivably, immuno- 
modulation by targeting synovial DC might provide a novel anti­
rheumatic strategy.
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Background Dendritic cells (DC) from both myeloid and lymphoid 
haematopoietic lineages comprise a complex network of professional 
antigen-presenting cells, directly linking innate and adaptive immunity. 
Although implicated in the pathogenesis of inflammatory arthritides, 
their subset analysis has been hampered by a lack of specific DC 
markers and reliable quantitation.
Objectives The study was conducted to quantify circulating plasmacy- 
S16 toid DC (pDC) and myeloid DC (mDC) populations in different chronic
inflammatory arthritides utilizing a novel assay involving the DC-specific 
markers BDCA-1 and BDCA-2.
Methods Peripheral blood (PB) was obtained from RA (n =  12), PsA 
(n =  13), AS (n = 1 1 )  and healthy donors (n =  12). Synovial fluids (SF) 
were also examined from a subset of PB samples (4 RA, 2 PsA, 1 AS). 
A white blood count (WBC) was performed on all samples, followed by 
DC enumeration using the blood DC enumeration kit (Miltenyi Biotec). 
Results Circulating PB mDC populations were significantly decreased 
in RA patients (P =  0.004), but not in PsA or AS patients, compared 
with healthy donors (normal =  1 75 x  102, RA =  95.5 x  102, PsA =  
141 x 1 0 2, AS =  152 x  102). Circulating PB pDC populations were 
significantly decreased in RA (P = 0 .01 ) and PsA (P = 0 .01 ) but not 
AS patients (normal =  137 x  102, RA =  54.6 x  1 02, PsA =  69.5 x  102, 
AS = 1  0 4 x  102). The mDC : pDC ratio in PB of all patient groups was 
similar to that in healthy donors, whereas mDC exceeded pDC in SF in 
all patient cohorts analyzed (RA 6.6 : 1, PsA 7.35 : 1 and AS 100:1). 
Conclusions We report the ex vivo tracking of circulating pDC and 
mDC populations, revealing significantly reduced numbers of pDC in 
RA and PsA and mDC in RA patients. mDC subsets appear to be the 
predominant population in SF in all patient cohorts studied. Under­
standing the biology of DC subsets in chronic inflammatory arthritis will 
elucidate their presumed critical role at the interface of innate and 
acquired (autoreactive) immune responses.
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Introduction Dendritic cells (DCs) determine the balance between tol­
erance and immunity in which Fc y receptors (FcyR) are thought to play 
a decisive role. Previously, we found that DCs from RA patients 
expressed a different FcyR profile.
Objective The aim of the study was to determine the potential differ­
ence in chemokine expression and production between DC from RA 
patients and healthy controls upon FcyR mediated triggering.
Methods Immature and mature DC were obtained using standardized 
protocols as described recently. The expressions of the chemokines 
DC-CK1, ELC, IL-8, MIP-1a, TARC and MDC were determined by 
using real-time quantitative RT-PCR techniques (PRISM). The produc­
tion of DC-CK1 was confirmed by using ELISA techniques. Triggering 
of FcyR was achieved by the addition of heat aggregated IgG 
immunoglobulins (HAGGS) to the culture for 48 hours.
Results Stimulation of FcyR resulted in a significantly decreased 
expression of DC-CK1 (35%), ELC (50%), IL-8 (640%) and TARC 
(39%) by DC from RA patients (n =  6). Although not significant, the 
same trend was observed for MIP-1a (160%). In contrast, a significant 
increase was seen for DC-CK1 (300%), ELC (1 20%), IL-8 (640%), 
MIP-1a (160%) and TARC (39%) upon triggering of FcyR on DC from 
healthy individuals (n =  5). MDC was the only chemokine that showed 
a decrease upon FcyR dependent stimulation of DC in both groups. By 
using ELISA techniques, we confirmed these data for DC-CK1 on the 
protein level. Triggering of FcyR led to a decreased (63%) production 
of DC-CK1 by DC from RA patients, whereas an increase (137%) was 
observed by those from controls.
Conclusion Our study lends strong support for a skewed FcyR 
balance toward the inhibitory subtype in RA, and shows the critical role 
for FcyR in the inhibition of chemokine production by DCs. Further­
more, our data show that FcyR triggering influences Toll-like receptor 
(LPS) mediated cell responses.
Available online http://arthritis-research.c0m/supplements/6/S 1
Phenotypic and functional deficiencies of monocyte 
derived dendritic cells in systemic lupus 
erythematosus patients 
C Scheinecker, M Kölle r, B Z w ö lfe r, JS Sm olen
Department of Rheumatology, Internal Medicine III, University of 
Vienna, Vienna, Austria
Arthritis Res Ther 2004 6(Suppl 1):49 (DOI 10.1186/ar1091) 
Background Systemic lupus erythematodes (SLE) represents an 
autoimmune disease for which alterations in T cells, B cells as well as 
various antigen-presenting cell (APC) populations have been described. 
Objective In order to better define APC-associated deficiencies we 
analyzed morphologic, phenotypic and functional characteristics of 
dendritic cells (DC) from SLE in patients as compared with healthy 
controls.
Methods Monocyte derived DC (MoDC) were generated by culturing 
monocytes with GM-CSF+IL-4 for 8 days and with LPS for additional
2 days. MoDC were analyzed at different stages of maturation for mor­
phologic, phenotypic and functional characteristics.
Results and Conclusion Analysis of MoDC at different stages of mat­
uration revealed substantial phenotypic and functional defects of 
MoDC from SLE as compared with healthy controls. In particular, we 
observed a significantly reduced upregulation of MHC class II mole­
cules on MoDC upon activation, which correlated with disease activity 
scores and functional deficiencies in mixed lymphocyte reaction experi­
ments. Our data imply a crucial role of APC in the immunologic imbal­
ance in SLE for foreign- and self-antigen reactivity.
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Background and Objective Dendritic Cells (DCs) play an important 
role in initiation and regulation of immune responses in arthritis, 
because these cells are crucial for the initiation of T cell immunity. Full 
mobilization of effector T cells depends on proper maturation of DCs. 
Current evidence indicates that the type of T cell response indeed cru­
cially depends on the activation status of DC. For example, antigen 
recognition on resting DCs can result in immuneregulation. In this study 
we explored the immunological effects of differentially matured DCs on 
the development of collagen-induced arthritis (CIA).
Methods Bone marrow derived DCs were cultured in the presence of 
GM-CSF with or without IL-4. Immature, TNF-a or LPS activated, 
antigen-pulsed DCs were used. At several time points before immu­
nization with bovine CII protein, mice were injected with DCs exposed 
to these different maturation stimuli. Mice were boosted on day21 
post-CII-immunization and disease course was monitored.
Results Although vaccination with immature or LPS activated DCs had 
no significant influence on disease course, administration of antigen- 
loaded, TNF-a modulated DCs resulted in a delayed onset of arthritis 
and a decreased clinical score. The effect was antigen-specific, as also 
evidenced when antibody titres were measured. A specific increment in 
the collagen-specific ‘Th1-associated' IgG2a response was observed. 
Remarkably, IgG1 was unaffected by this vaccination.
Conclusions CIA can be prevented through vaccination with TNF-a 
matured DCs in an antigen-specific manner. These findings provide a 
rational to employ DCs in treatment or prevention of arthritis.
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Objective Dendritic cells (DC) are thought to play an important role in 
the pathogenesis of rheumatoid arthritis (RA). In RA, fully matured APC 
are present in the inflamed synovial tissue clustered around activated 
T cells. Because DC maturation and cytokine production are NF-kB 
dependent, we hypothesized that blocking NF-kB activity in DC by 
selectively targeting IKKp with a specific NEMO binding domain (NBD) 
peptide could inhibit the maturation of DC and thereby modulate the 
immune response.
Methods Immature DC were obtained by culturing freshly isolated 
monocytes in the presence of GM-CSF and IL-4. On day 6 immature 
DC were incubated with the NBD peptide (WT versus MUT) in the 
presence of maturation factors. DC were analyzed for NF-k B activity, 
surface marker expression, cytokine production and interaction with 
naive T cells. Furthermore, we investigated the effect of ia injection of 
the NBD peptide in adjuvant arthritis in rats.
Results NF-kB blockade by the NBD peptide resulted in strongly 
reduced maturation of DC. In addition, IL-6, IL-12 and TNF-a production 
was dose dependently blocked. Interestingly, NBD peptide treatment 
resulted in increased CCR7 expression. Coculture with naïve T cells 
resulted in reduced proliferation and differentiation. In vivo, injection of 
the NBD peptide resulted in reduced paw swelling in arthritic rats. 
Conclusions Inhibiting NF-kB with the NBD peptide in DC results in an 
immature phenotype with increased CCR7 expression. The enhanced 
CCR7 expression may promote migration to draining lymph nodes and 
presentation of antigen in the absence of costimulation. These data 
strongly suggest that targeting NF-kB in DC could be beneficial in the 
treatment of arthritis, which is supported by preliminary data in rat adju­
vant arthritis.
Joint destruction/tissue engineering
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Background and Objective CD44 mediates cell-matrix interaction and 
is thought to play a role in cell adhesion, fusion and migration. Blocking 
of CD44 is considered as potential target in the therapy of rheumatoid 
arthritis.
Methods To elucidate the role of CD44 in arthritis, human TNF trans­
genic (hTNFtg) mice were crossed with CD44 knockout mice. S17
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Results Clinical evaluation revealed a significantly increased severity of 
arthritis in CD44-/- hTNFtg mice than in hTNFtg mice. Wild-type mice 
and CD44-/- mice were normal. Histologically, bone destruction was 
dramatically increased in the arthritic paws of CD44-/- hTNFtg mice. 
Changes were based on a significant increase of size and number of 
osteoclasts in the synovial inflammatory tissue. Ex vivo analysis of osteo- 
clastogenesis revealed that osteoclasts differentiated more rapidly and 
were increased in size and number in CD44-/- hTNFtg mice compared 
with hTNFtg controls. In addition, bone resorption assay showed 
increased 'pit' formation by osteoclasts of CD44-/- hTNFtg mice. 
Conclusion CD44 deficiency does not block but rather increases the 
severity of TNF-mediated arthritis. This was due to increased bone 
damage caused by deregulation of osteoclastogenesis. We conclude 
that CD44 is of benefit for TNF-mediated arthritis because of its regula­
tory role on osteoclasts.
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Objectives In this study we attempted to map the molecular events 
that underlie the clinical effects of glucocorticoid (GC) treatment in 
patients.
Methods DNA arrays and immunohistochemical staining was used for 
comparison of patient material isolated before and after intra-articular 
glucocorticoid (GC) treatment. Gene expression data analysis was per­
formed in the GeneSpring™ software.
Results Hierarchical clustering of gene expression data could distin­
guish samples taken before from those taken after treatment to a sur­
prisingly high degree, in spite of anticipated individual and experimental 
variations. Patterns were further analyzed by identification of genes 
with both statistically significant differential expression (P <  0.05) using 
the cross gene error model implemented in GeneSpring™, and greater 
than twofold differential expression. Twelve genes satisfying both of 
these criteria were found, including matrix metalloproteinase (MMP)-1 
and MMP-3, for which mRNA expression was downregulated, and 
tissue inhibitor of MMP (TIMP)-1 and TIMP-4, for which mRNA expres­
sion was upregulated by GC treatment. Immunohistochemical staining 
for several MMP and TIMP molecules confirmed data for MMP-1 and 
MMP-3 on a protein level, whereas the result for TIMP-1 and other 
TIMPs revealed reduced protein expression of these molecules. 
Conclusions Our data demonstrate that DNA arrays may be used for 
evaluating the molecular effects of novel as well as established thera­
pies, but also that data should be interpreted with caution concerning 
their ability to predict therapeutic effects at the protein level.
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Objective Interferon (IFN)-p is thought to inhibit the expression of 
S18 proinflammatory cytokines and to enhance the production of anti­
inflammatory proteins such as IL-1Ra. More recently it was shown that 
IFN-P is important in maintaining homeostasis of bone resorption. 
Because systemic treatment does not appear to be effective in RA 
patients possibly because of the short half-life of IFN protein, we 
studied the potential of intra-articular gene therapy using an adenoviral 
vector to determine whether local constitutive expression of IFN-p in 
the joint might have a beneficial effect.
Methods Three different dosages (109, 1010 and 1011 viral particles) 
of an adenoviral vector containing the gene for rat IFN-P or LacZ 
(Ad.IFN-beta and Ad.LacZ) were injected into the right ankle joints of 
rats with adjuvant arthritis (AA) on day 12 after adjuvant immunization. 
Joints were harvested 2 weeks later. The effect of IFN-P on paw 
swelling measured by plethysmometry, bone degradation and histo­
logic joint damage was assessed.
Results In the rats treated with the highest dose of Ad.IFN-beta 
reduced paw swelling was observed (P = 0 .0 2 2  Ad.IFN-beta versus 
Ad.LacZ). In addition, a clear reduction in paw swelling was seen in the 
left uninjected paw. Moreover, the IFN-p-treated animals had signifi­
cantly less cartilage and bone destruction (P =  0.05) in both the right 
and left paws as compared with control animals.
Conclusion We demonstrate that adenoviral in vivo gene transfer of 
IFN-p cDNA into the synovium reduces the severity of inflammation of 
AA in rats. In addition, an even more potent effect was found on articu­
lar cartilage and bone destruction. Furthermore, injection of Ad.IFN- 
beta into a single paw can suppress inflammation and joint degradation 
in the contralateral joints. Thus, treatment of a single joint by local deliv­
ery of the IFN-P gene could protect multiple joints.
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Chondrocytes express RANKL and its receptor RANK, implicating the 
involvement of this pathway in cartilage damage. However, a direct role 
of RANKL in cartilage destruction has not yet been identified. Here, we 
used local and systemic osteoprotegerin (OPG) treatment to inactivate 
RANKL in different arthritis models. We demonstrated that inactivation 
of RANKL did not suppress cartilage breakdown in a local T-cell IL-17- 
induced joint pathology, but completely prevented cartilage erosion in 
collagen-induced arthritis, which is mediated by T cells and immune 
complexes. Synovial inactivation of RANKL by local OPG gene therapy 
in collagen-induced arthritis resulted in a chronic type 2 inflammation 
characterized by abundant expression of IL-4 and protection of carti­
lage erosion. Microarray analysis revealed abundant expression of YM1 
and arginase, which are specific markers of the macrophage M2 phe­
notype (alternative activated macrophage). Furthermore, protease spe­
cific inhibitors and Fc receptor type II are upregulated by OPG. 
Changes in expression of catabolic mediators and inhibitors in the syn­
ovial infiltrate, including the key catabolic cytokine in cartilage destruc­
tion IL-1, contribute to the cartilage protective effect of OPG. These 
data provide evidence that the cartilage protective effect of OPG in 
collagen arthritis is mediated by induction of a nondestructive type 2 
synovitis.
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Background The healing capacity of articular cartilage is very limited in 
the adult. Therefore, tissue engineering techniques were developed to 
treat cartilage lesions.
Objective Because high expression of type II collagen is of importance 
for the properties of cartilage after transplantation, we investigated 
whether the growth factor BMP-2 may modulate the chondrogenic 
phenotype in monolayer cell cultures (2D) and in three-dimensional 
culture (3D) systems.
Methods Chondrocytes from articular knee cartilage of five individuals 
were isolated and expanded under GMP conditions suitable for clinical 
purposes. Cells were seeded either in 2D cultures or embedded in 
alginate beads (3D) in the presence or absence of human recombinant 
BMP-2 (hr-BMP-2). Then, cells were harvested and analysis of the 
chondrogenic phenotype was performed using quantitative RT-PCR, 
immunocytochemistry and ELISA methods.
Results Expansion of chondrocytes in primary culture (P0) or in first 
subculture (P1) did not yield populations enriched for dedifferentiated 
or hypertrophic cells, because type X collagen encoding mRNA was 
detectable only at very low copy numbers. Seeding P1 chondrocytes in 
3D culture significantly reduced type I collagen, BMP-4 and IL-18, and 
induced type II collagen and BMP-2 encoding mRNA. Suppression of 
IL-1 ß and induction of IL-10 were noted but were not statistically signif­
icant. At P2, these changes were still evident. Addition of BMP-2 to 2D 
chondrocytes had no effect on type II collagen or IL-1ß mRNA 
amounts. In contrast, in 3D chondrocytes BMP-2 induced type II colla­
gen and reduced IL-1 mRNA amounts. This was also seen by ELISA 
and immunocytochemistry.
Conclusions We conclude that chondrocytes during expansion for 
ACT may benefit from BMP-2 activation only when seeded in an appro­
priate 3D culture system.
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Background We tested the hypothesis that a tissue engineering 
approach using chemoattractant molecules will allow in situ recruit­
ment of human bone marrow mesenchymal stem cells (MSC) to sites 
of degenerated articular cartilage.
Objective The aim of our ongoing study is to characterize molecules 
that are involved in chondrogenesis and chemotaxis of MSC.
Methods Human bone marrow aspirates were used to isolate MSC. 
The culture homogeneity was verified by FACS analysis (CD14- , 
CD34- , CD45- , CD105+, CD166+). For differentiation, MSC were cen­
trifuged to form high-density cultures and different TGFs were added. 
Chondrogenesis was documented by Alcian blue, type II collagen stain­
ing and by real-time PCR of marker genes. Chemotaxis was analyzed by 
chemokine receptor analyses and transwell chamber assays.
Results The histological staining showed BMP-2 promotes differentia­
tion along the chondrogenic lineage. Matrix formation was comparable 
to MSC stimulated with TGF-P3. The results suggest a synergistic stim­
ulation on chondrogenic differentiation with BMP-2 and TGF-P3. Differ­
entiation was further demonstrated by the induction of type II collagen, 
aggrecan, SOX-9 and link protein on the gene expression level. Fur­
thermore, for the first time, expression of chemokine receptors of all 
four chemokine subfamilies was proven by RT-PCR and subsequent 
sequence analysis, as well as at the protein level using specific anti­
bodies. The chemotactic activity in 24-transwell chemotaxis chambers 
was demonstrated for, for example, SDF1a.
Conclusion These findings demonstrate that chondrogenic development 
of MSC is inducible by different TGF-P3 superfamily growth factors 
including BMP-2. Additionally, MSC express chemokine receptors rele­
vant for chemotaxis or in situ recruitment for cartilage regeneration.
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IL-17 is a proinflammatory cytokine that is suspected to be involved in 
development of rheumatoid arthritis (RA). However, the role of 
IL-17-IL-17 receptor signaling in the effector phase of arthritis, includ­
ing requirement of this signaling pathway in synoviocytes, is still not 
fully elucidated. Here we demonstrate, using IL-17 receptor deficient 
(IL-17R-/-) mice, a requirement for IL-17R signaling in immune reactiv­
ity and progression of synovitis and bone erosion in a T cell mediated 
mBSA arthritis model and chronic streptococcal cell wall arthritis. Of 
great interest, chimeric mice of host wild-type (wt) and donor IL-17R-/- 
bone marrow (BM) cells developed chronic synovitis similar to that in 
w t/w t chimeras. In contrast, chimeric mice of host IL-17R-/- and donor 
w t BM cells were protected from progressive synovitis similar to 
IL-17R-/-/  IL-17R-/- chimeras, suggesting a crucial role of resident syn­
ovial cells. Weakened mobilization of neutrophils into the joint and 
downregulation of synovial mRNA expression for leukocyte specific 
chemokines and selectins, and MMP-1 was found in IL-17R-/- mice.
These data suggest that, in addition to the role played by IL-17-IL-17R 
signaling in development of immunity, synovial IL-17-IL-17R signaling 
plays a critical role in the effector phase of arthritis. Activation of IL-17R 
on fibroblast-like synoviocytes appears pivotal.
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TRAIL-induced rheumatoid arthritis fibroblast-like 
synoviocyte proliferation is inhibited by OPG
J M ore l1,2, R A udo2, V  Descham ps2, B C om be1,2
departm ent of Immuno-rheumatology, CHU Lapeyronie, Montpellier,
France; 2Inserm U454, Montpellier, France
Arthritis Res Ther 2004 6(Suppl 1):59 (DOI 10.1186/ar1101)
TNF-a related apoptosis inducing ligand (TRAIL) is a proapoptotic 
factor that can also induce cell proliferation. The role of TRAIL in 
rheumatoid arthritis (RA) is still unclear. We investigated the effect of 
TRAIL on RA fibroblast-like synoviocyte (FLS) proliferation. TRAIL 
induces RA FLS proliferation in a dose-dependent manner, with a 
maximum proliferation at 0.5 nmol/l (P < 0 .0 5 ; n =  5). This proliferation 
could be prevented by the natural TRAIL inhibitor osteoprotegerin 
(OPG) and a TRAIL antibody. By flow cytometry, we analyzed TRAIL 
receptors (DR4, DR5 and DcR2). RA FLS constitutively expressed 
DR5 (n =  5) and three out five RA FLS expressed DR4. Interestingly,
RA FLS proliferate more after TRAIL stimulation when expressing both S19
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DR4 and DR5, suggesting a cumulative effect of the two receptors. DR5 
receptor mediates the signal-inducing cell proliferation because stimula­
tion with an agonistic anti-DR5 antibody induces RA synoviocyte prolifer­
ation (n =  4; P  <  0.05). Next, we investigated which cells in the synovium 
could produce TRAIL and OPG. In RA FLS, TRAIL was detected at the 
mRNA level after IL-1 p and TNF-a stimulation but not at the protein level. 
OPG was constitutively produced (2 ng/ml) and upregulated by IL-1 p 
(14-fold) and TNF-a (5-fold) but not IL-18. On RA synovial T cells, TRAIL 
was constitutively expressed. Our results show that TRAIL induces RA 
FLS proliferation. TRAIL produced on synovial T cells may interact with 
RA FLS expressing DR4 and DR5 to induce FLS proliferation. OPG 
inhibits TRAIL induced RA FLS proliferation. This novel propriety of OPG 
may be another explanation for its bone protective role in RA.
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Fibroblasts can be isolated from rheumatoid arthritis (RA) synovial fluid 
(Sfld), and these cells may be derived from the synovium. Although 
normal tissues do not express DR5 protein, most cancerous tissues 
express high levels of DR5. Synovial fibroblasts from RA synovium share 
expression of DR5 protein with transformed cells. Our objective was to 
characterize fibroblasts from RA Sfld using an anti-DR5 monoclonal 
antibody. Sfld mononuclear cells were cultured from 50 patients with 
RA, 20 patients with seronegative arthritis, 20 patients with osteoarthri­
tis (OA), and 15 patients with unclassified monoarthritis or oligoarthritis. 
Progressive growth of spindle-shaped cells was observed in some cul­
tures. By the third passage 100% of cells were fibroblasts (Thy-1+, 
CD45- , CD68-). Fibroblasts were stained with a PE-conjugated anti- 
DR5 antibody and examined by flow cytometry. Fibroblasts grew from 
35 of 50 RA Sfld samples. Twenty-six of these 35 were DR5+ (>95%  
positive cells; MFI relative to isotype control, 13.97 ±2.5). Fibroblasts 
also grew from Sfld in six out of 20 seronegative arthritis, four out of 
20 OA, and five out of 15 unclassified monoarthritis or oligoarthritis 
patients. All these were DR5- (MFI relative to isotype control, 
1.2 ±  0.23). Ten out of 10 fibroblast lines from joint replacement surgery 
or synovectomy specimens of RA were DR5+. All fibroblast lines from 
the synovium of 10 OA patients were DR5- , as were fibroblasts from the 
skin of five healthy subjects. DR5+ Sfib cultures underwent apoptosis 
when treated in vitro with an anti-DR5 antibody, as determined by pro- 
pidium iodide and annexin V staining. These results suggest that fibrob­
last-like cells from Sfld of RA are of at least two different lineages. Those 
expressing DR5 protein share this characteristic with transformed cells 
and with synovial fibroblasts from RA synovial membrane, and more 
likely derive from the synovium. The origin of DR5- Sfld fibroblasts 
remains to be determined. Because all RA patients with DR5- Sfld 
fibroblasts had active disease, we do not believe that DR5- cells are 
derived from ‘burnt out' synovial membrane.
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Background Leflunomide is an immunomodulatory agent used for the 
treatment of rheumatoid arthritis (RA) and is known to inhibit the prolif­
eration of several cell types, including T lymphocytes.
Objectives Because pannus formation due to excessive synoviocyte 
S20 proliferation is generally associated with the development of RA, we
sought to determine the effects of A77-1726, the active metabolite of 
leflunomide, on synovial fibroblast proliferation.
Methods Cell viability was investigated by measuring at 490 nm the 
formation of formazan from MTS tetrazolium, and cell proliferation by 
determination of thymidine incorporation and cell counts.
Results Whereas A77-1726 alone had no significant effects on prolif­
eration, it dramatically increased the mitogenic effects of IL-1 p. Then 
we investigated the possible mechanisms of this effect of A77-1726 
(i.e. inhibition of DHODH, of tyrosine kinases and COX). The effect 
was not mediated through inhibition of DHODH because it was not 
reversed by addition of exogenous uridine. It was not due to inhibition 
of tyrosine kinases either, because the broad-range inhibitor genistein 
and the src tyrosine kinase inhibitor PP1 blocked rather than increased 
IL-1 p effects. Finally, although in the absence of IL-1 p PGE2 dose- 
dependently decreased proliferation, it had no effect in the presence of 
IL-1 p, and treatment with indomethacin did not consistently reproduce 
the effects of A77-1726.
Conclusions The mitogenic effects of A77-1726 in presence of IL-1 p 
may thus be independent on DHODH and tyrosine kinase inhibition, 
whereas the role of COX is more uncertain; identification of involved 
mechanisms may prove useful for the development of related com­
pounds or new therapeutic strategies.
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Background Focal and systemic bone loss in rheumatoid arthritis (RA) 
involves several cytokines such as RANKL, which is secreted by both 
osteoblasts and activated lymphocytes, and TNF-a. Anti-TNF-a anti­
bodies decrease articular inflammation and bone erosions, but the 
effect on bone remains to be elucidated. Osteoprotegerin (OPG) 
inhibits bone resorption.
Objective We conducted the study to evaluate the respective and 
combined effect of OPG and anti-TNF-a antibodies on inflammation 
and on bone remodelling.
Methods DBA/1 mice were immunized then treated at the onset of 
arthritis with OPG-Fc or anti-TNF-a antibodies or with both OPG-Fc +  
anti-TNF-a antibodies or saline; one group of mice remained untreated 
(naïve). Deoxypyridinoline changes (AD-Pyr) in urine, bone mineral 
density gain (ABMD) at the total body level, and histomorphometric 
parameters at the femur metaphysis were measured.
Results Anti-TNF-a antibodies but not OPG decreased clinical and 
histological scores (P <  0.02 versus saline). ABMD was lower in saline- 
treated CIA mice than in naïve mice (P <  0.01), suggesting the effect of 
inflammation on bone loss. OPG and anti-TNF-a antibodies increased 
ABMD compared with saline (P <  0.001 and P <  0.05, respectively). 
AD-Pyr decreased by 65% with OPG and by 7% with saline 
(P <0.001), but by 13% when mice were treated with TNF-a antibod­
ies (NS). Compared with saline, OPG induced increased trabecular 
(Tb) bone volume (P <  0.02), decreased Tb spacing (P <  0.02) and 
decreased BFR/BS (P < 0 .01 ). In contrast, the anti-TNF-a antibody 
treated group showed no significant changes in Tb bone volume and 
Tb spacing compared with saline, but Tb thickness was greater 
(P <0 .02), close to that in naïve mice, suggesting a protective effect 
on bone formation. There was no additive effect of OPG and anti- 
TNF-a antibodies on any parameter.
Conclusion Administration of OPG and anti-TNF-a antibodies pre­
vented bone loss in CIA mice through distinct mechanisms involving
Available online http://arthritis-research.c0m/supplements/6/S 1
inhibition of bone resorption and formation. Combinations of both treat­
ments must be further investigated.
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Local bone erosion and systemic bone loss are hallmarks of rheuma­
toid arthritis and cause progressive disability. Tumour necrosis factor 
(TNF) is a key mediator of arthritis and acts catabolically on bone by 
stimulating bone resorption and inhibiting bone formation. We hypothe­
sized that the concerted action of anti-TNF, which reduces inflamma­
tion, and of PTH, which stimulates bone formation, or of OPG, which 
blocks bone resorption, could lead to repair of local bone erosions and 
reversal of systemic bone loss. To test this, human TNF-transgenic 
(hTNFtg) mice with established erosive arthritis and systemic bone loss 
were treated with PTH, OPG and anti-TNF, alone or in combination. 
Local bone erosions almost fully regressed, upon combined treatment 
with anti-TNF and PTH and/or OPG, suggesting repair of inflammatory 
skeletal lesions. In contrast, OPG and anti-TNF alone led to arrest of 
bone erosions but did not achieve repair. Treatment with PTH alone 
had no influence on the progression of bone erosions. Local bone ero­
sions showed all signs of new bone formation such as the presence of 
osteoblasts, osteoid formation and mineralization. Furthermore, sys­
temic bone loss was completely reversed upon combined treatment 
and this effect was mediated by osteoblast stimulation and osteoclast 
blockade. In summary, we conclude that local joint destruction and sys­
temic inflammatory bone loss due to TNF can regress, and that repair 
requires a combined approach by reducing inflammation, blocking 
bone resorption or stimulating bone formation.
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Background Oxidative stress is thought to underlie the altered patho­
genic behavior of T cells in rheumatoid arthritis (RA). We recently 
demonstrated that intracellular signaling by Ras family GTPases leads to 
ROS production in RA synovial fluid (SF) T cells. However, other cellular 
sources of ROS may cause oxidative stress in RA synovial tissue (ST). 
Objectives The study was conducted to determine whether T cells or 
other cells spontaneously produce ROS in RA ST, to determine the 
specificity of T cell ROS production in long-standing RA versus early 
RA and osteoarthritis (OA) T cells, and to identify signaling pathways 
producing ROS in RA ST and SF T cells.
Methods ROS production was assessed using ROS-dependent polymer­
ization of diaminobenzidine (DAB) on cryostat sections of ST from patients 
with long-standing RA, early RA, and OA (n = 1 0  patients in each group),
purified RA patient peripheral blood (PB) and SF mononuclear cells, and 
purified T cells (n =  4), and oxidation of the dye DCF by FACS analysis of 
purified RA PB and SF T cells (n =  10), in the absence or presence of 
pharmacological inhibitors. Cryostat sections were double labelled with 
DAB and cell-specific antibodies to quantify ROS-producing cells.
Results ROS production was observed in both longstanding and early 
RA, but not OA ST. ROS production was observed only in T cells 
(68%) and neutrophils (15%). In RA ST, ROS producing T cells were 
observed in the synovial sublining and perivascular tissue. Catalase 
and BAPTA-AM, but not other ROS inhibitors, blocked ROS produc­
tion in ST and SF T cells. Intracellular ROS production is detected in 
ST of patients with RA but not OA. T cells are the major source of intra­
cellular ROS production in RA ST. Conserved signaling pathways reg­
ulate ROS production in ST, SF and Jurkat T cells. ROS production is 
observed in recently extravasated T cells, indicating that oxidative 
stress is an early event affecting T cell function in the RA synovial joint.
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Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown 
etiology that primarily affects the joints. Recently, a T cell receptor trans­
genic murine model yielded novel insights. K/BxN TCR transgenic mice 
spontaneously develop an autoimmune arthritis that resembles human 
RA. Arthritis development depends on the recognition of the ubiqui­
tously expressed glycolytic enzyme GPI by both the transgenic T cells 
and B lymphocytes. Here we show that immunization with heterologous 
GPI in adjuvant induces a symmetric polyarthritis of the small distal 
joints in genetically susceptible mice. The course of GPI-induced arthri­
tis is highly predictable: clinically overt arthritis develops 9 -1 0  days after 
immunization, reaches its maximum at D15 and then slowly resolves. 
Histologically, the disease is characterized by early synovitis followed by 
massive cartilage destruction and erosions of the bones and later reso­
lution of the inflammation, fibrosis, and repair processes. Although anti­
body titers in susceptible and nonsusceptible mouse strains are high, 
transfer of purified total IgG of sick mice alone do not transfer disease. 
Anyway, antibodies seem to play a major role since Fc-receptor y-chain 
deficient mice develop disease with a much lower frequency and 
reduced severity than the wild-type mice. Treatment with a depleting 
monoclonal anti-CD4 antibody completely prevents disease. Depletion 
of CD4+ T cells during disease leads to a rapid resolution of arthritis. 
Therefore, CD4+ T cells are important for both the induction of the 
disease and the effector phase. Thus, GPI-induced arthritis in normal 
mice bridges the gap between the transgenic K/BxN model and the 
highly complex human situation, thereby providing a model in which both 
the induction and effector phase of antigen specific arthritis can be dis­
sected, and preventive and therapeutic strategies evaluated.
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Background Myeloid related protein (MRP)8 and MRP14 are 
expressed in early monocytes, whereas CD163 is marker for mature 
tissue macrophages. S21
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Objective To analyse macrophage subsets in RA and SpA, and the 
effect of infliximab on the synovial infiltration of these subsets.
Methods Paired synovium and synovial fluid (SF) were collected in
20 RA and 30 SpA patients. In nine SpA patients, synovium was also 
obtained after 12 weeks of infliximab treatment. The levels of expres­
sion of MRP8, MRP14, CD163 and CD68 were analyzed by immuno- 
histochemistry on frozen sections. Levels of MRP8/MRP14 in SF were 
determined by ELISA.
Results In inflammatory arthritis, MRP8, MRP14, CD163 and CD68 
positive cells were abundant in the lining and sublining layer. The 
expression of CD68 and CD163 exhibited a cellular pattern. The 
MRP8 and MRP14 expression was characterized by a cellular staining, 
with in some samples also an extracellular and perivascular pattern. 
Comparing RA and SpA, CD68-positive macrophages were equally 
present (lining P  = 0 .463 , sublining P  =0 .235), whereas MRP8 
expression was higher in the lining of RA synovium (P =  0.025) and 
CD 163-positive cells were more prominent in SpA synovium (lining 
P  <0 .001 , sublining P  =0 .017). No differences for MRP8, MRP14, 
CD163 or CD68 were seen between the SpA subgroups. Confirming 
that these markers identify different macrophage subsets, the expres­
sion of MRP8 and MRP14 was more reduced after infliximab than 
CD163 (MRP8: lining P  = 0 .038 , sublining P  = 0 .02 3 ; MRP14: lining 
P  =0 .088 , sublining P  = 0 .03 6 ; CD163: lining P  = 0 .119 , sublining 
P  =0 .125). Local secretion of soluble MRP8/MRP14 was evidenced 
by high SF levels (RA 24 530 ng/ml, SpA 4152ng/m l), which were 
higher than in serum (RA 20-fold, SpA 6-fold).
Conclusion MRP8/MRP14 and CD163 identify different macrophage 
subsets as evidenced by the differential expression in RA versus SpA, 
and by the differential effect of infliximab on the synovial expression of 
these markers
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Background Prosthesis loosening fibroblasts (PLF) contribute signifi­
cantly to the pathogenesis of aseptic prosthesis loosening (APL) and 
show similarities to rheumatoid arthritis synovial fibroblasts (RA-SF). 
Based on data that have linked the increased expression of the small 
ubiquitin-like modifier SUMO-1 to the resistance of RA-SF against 
apoptosis, we investigated the expression of SUMO-1 in APL and used 
gene transfer of the SUMO protease SENP1 to study consequences of 
SUMOylation in PLF.
Methods We used in situ hybridization (ISH) to study the expression of 
SUMO-1 in APL interface tissues. Quantitative PCR and Western blot 
were applied to measure the expression of SUMO-1 in PLF in compari­
son with RA-SF. Confocal microscopy of PLF transfected with GFP- 
labeled wild type (wt) or mutant (mt) gene constructs of SENP1 was 
performed to investigate the cellular localization of SUMO-1. To study 
the functional contribution of SUMO-1 to the apoptosis of PLF, 
SENP1wt-, SENP1mt- and mock-transfected PLF were stimulated with 
FasL, and apoptosis was determined by a histon fragmentation assay. 
Results ISH revealed marked expression of SUMO-1 in all tissues, with 
most prominent staining at sites attached to bone. The expression of 
SUMO-1 in PLF was comparable with that in RA-SF. Confocal 
microscopy revealed localization of SUMO-1 mainly in nuclear PML- 
bodies. After transfection of PLF with SENP1, high levels of SENP1 
mRNA were measured (up to 472-fold versus endogenous SENP-1). 
Transfection of PLF with SENP1wt decreased the nuclear staining for 
SUMO-1, and increased significantly FasL-induced apoptosis (155% 
S22 versus SENP-1mt). Spontaneous cell death remained unaffected.
Conclusion The data suggest that SUMO-1 is involved in the activa­
tion of PLF and RA-SF by preventing these cells from Fas-induced 
apoptosis. The modification of nuclear proteins by SUMO-1 appears to 
contribute to the antiapoptotic effects of SUMO-1. By de-conjugating 
SUMO-1 from its nuclear substrates, SENP1 can regulate the apop- 
totic response of PLF.
Genomics and signal transduction
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Background In rheumatoid arthritis (RA), monocytes are of central 
importance in the chronic inflammatory immune response. These cells 
may display diagnostic markers and provide insight into pathophysio­
logical pathways in RA.
O bjective To identify characteristic expression patterns in rheumatoid 
arthritis (RA), highly purified peripheral blood monocytes were investi­
gated.
M ethods Monocytes from five normal donors (ND) and six patients 
with active RA were purified by erythrocyte lysis and CD1 4-positive 
selection at constant low temperature (4°C) conditions to minimize in 
vitro induced artefacts. Gene expression was detected by Affymetrix 
HG U133A hybridization. Bioinformatic analysis included MAS5.0 
image analysis, statistical methods (t-test; Mann-Whitney) and cluster 
analysis (genes@work).
Results Array analysis revealed about 50% present calls in ND or RA 
monocytes. MAS5.0 comparison expression analysis revealed 605 
genes that were significantly changed in more than 50% of all RA 
versus ND pair-wise comparisons. Statistical methods revealed that 
260 of these genes were significantly different (P <  0.05). Selection 
and reduction by fold changes above 1.6 and statistical methods 
reduced the number of differentially expressed genes to 152. This set 
of genes is implicated in cellular processes that are involved in cell 
communication (cytokines, chemokines and their receptors), intracellu­
lar signalling, transcription, defense response, apoptosis and heat 
shock responses. Hierarchical cluster analysis based on these selected 
genes separated into two branches, one for ND and one for RA 
patients.
Conclusion Gene expression profiling of separated peripheral blood 
monocytes identified a characteristic gene pattern that is involved in 
the activation of monocytes, and clearly indicates an inflammatory 
process in RA. These results will be compared with expression profiles 
in other inflammatory rheumatic diseases and further analyzed for domi­
nant pathophysiological pathways in a search for new candidates for 
targeted therapy in RA.
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diagnosis of rheumatoid arthritis and prognosis of 
anti-TNF-a therapy
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Background In rheumatoid arthritis (RA) macrophages (Mf) play a 
pivotal role. They become highly activated in synovitis and at the carti-
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lage-pannus junction. Furthermore, therapeutic neutralization of mole­
cules produced by activated Mf lead to clinical improvement in RA, and 
circulating monocytes (MO) of the peripheral blood in patients with RA 
spontaneously express proinflammatory genes (IL-1 P, IL-6, TNF). 
Methods A custom RA-MO cDNA microarray was generated using dif­
ferentially expressed genes obtained from gene subtraction and from 
comparative whole genome wide U133A analysis in normal donors, 
active and anti-TNF-a treated RA patients. Genes were selected using 
MAS 5.0, multtest and PAM. The custom microarray consists of 313 
genes including guide dots, and positive (housekeeping genes and 
spike controls) and negative controls for image and statistical analysis. 
Each probe was spotted in 16 replicates.
Results The RA-MO chipset-II was validated using the following: non­
stimulated and LPS, PMA, Vit.D3+LPS, PMA+LPS stimulated U937 
cells; nonstimulated and LPS stimulated healthy donor MO; MO from 
normal donors (n =  3) and RA patients before and during anti-TNF-a 
treatment (n =  5 each); and synovial tissue from normal individuals 
(n =  2) and RA patients (n = 2 ). Not only LPS/PMA regulated genes 
but also RA specific and anti-TNF-a regulated genes were validated. In 
addition, we could clarify whether these genes are differentially tran­
scribed only in MO or whether they can also be found in RA tissue Mf. 
Our data indicate a high degree of reproducibility that is sufficient for 
diagnostic applications and therapy monitoring.
Conclusion The RA-MO chipset-II microarray is competitive and flexi­
ble for enlargement of the number of genes. The current gene selection 
will contribute to validating the role of monocytes in disease activity, to 
therapeutic interventions, and may improve the knowledge on the regu­
lation of pathways in activated monocytes in chronic inflammation.
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Background Inadequate functioning of NF-kB is implicated in many 
diseases, such as rheumatoid arthritis (RA), and increased activation of 
NF-kB in synovial tissue precedes the clinical manifestation of experi­
mental arthritis.
Objective The aim of the study was to develop NF-k B reporter cell- 
lines that can be used for real-time evaluation of NF-k B activation in 
knee joints during experimental arthritis in living animals.
Methods For determination of NF-k B transcription activity, an eukaryotic 
expression vector was created containing five tandemly arranged NF-k B 
binding sites (5'-GGGACTTTCC-3') regulating luciferase expression. 
Cell lines were selected on stable incorporation of 5 x  NF-k B luciferase 
and responsiveness was tested toward NF-k B inducing stimuli.
Results These cell-lines, derived from fibroblasts, chondrocytes and 
thymocytes, showed good cytokine responsiveness toward IL-1, IL-17, 
IL-18, and TNF. We showed that these cells could also be used in in 
vitro inhibition assays using cytokine protein antagonist (e.g. IL-1Ra 
and IL-18BPc) or RNA interference. By transplanting these cells into 
HLA matched recipients we were able to image in real time NF-kB acti­
vation in knee joints of mice with IL-1- or SCW-induced inflammation 
using a cooled-charge-coupled device (CCCD) camera. Interestingly, 
NF-kB activation was also activated at sites remote from the monokine 
or SC W  injection sites. Synovial mRNA revealed a striking upregulation 
of IL-1 in both SC W  challenged and contralateral knee joint. This effect 
was confirmed by pretreatment of mice with neutralizing anti-IL-1 Abs, 
which markedly prevented the NF-kB activation in the contralateral 
naive joints.
Conclusion These reporter cell-lines can be a valuable tool to study 
the role of NF-k B activation in arthritis and to evaluate cytokine/NF-KB 
based inhibition therapies. Furthermore, we show that local induction of 
experimental arthritis results in contralateral NF-k B activation, which is 
dependent on IL-1.
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Background Thymosin p4 (Tb4) is a 4.9 kDa ubiquitously expressed 
intracellular peptide known to sequester G-actin, with a growing 
number of extracellular biological functions. We have shown that oxida­
tion of its single methionine residue at position 6 (Tb4 sulphoxide 
[Tb4SO]) gives the peptide potent anti-inflammatory properties. In 
addition, Tb4 promotes wound healing in various in vitro and in vivo 
models. The mechanism by which Tb4SO exerts its extracellular bio­
logical functions is unknown. Its cell receptor remains unidentified and 
intracellular signalling consequences of Tb4SO require elucidation.
Objective The study was conducted to investigate the intracellular sig­
nalling consequences of the addition of Tb4SO to various cell types, 
specifically MAP kinase activation.
Methods Cell types used were treated with Tb4SO and lysed using 
RIPA buffer. Lysates were run on SDS PAGE, transferred to PVDF 
membrane and probed with antiphospho ERK1/2, p38, JNK1/2 or AKT 
antibodies. Membranes were then stripped and reprobed with pan­
antibodies to allow normalization of samples.
Results Tb4SO induced the phosphorylation of ERK1/2 in peripheral 
blood-derived monocytes in dose-dependent manner. This was inhib­
ited by addition of U01 26, an inhibitor of the upstream activator of 
ERK1/2, implicating ERK1/2 in Tb4SO-mediated functions in mono­
cytes. Neither p38 MAPK nor JNK1/2 were activated in peripheral 
blood monocytes. In peripheral blood-derived macrophages, Tb4SO 
induced rapid and marked activation p38 MAPK, pAkt and ERK1/2, but 
not of JNK (p-JNK1/2). Interestingly, only JNK1 was activated by 
Tb4SO in HeLa cells, and this occurred in a delayed (after 15 min) and 
transient manner. Short-term activation of JNKs has previously been 
shown to be involved in the upregulation of apoptosis. Preliminary 
studies have shown an acceleration in neutrophil but not monocyte/ 
macrophage apoptosis in response to Tb4SO.
Conclusions These observations suggest that Tb4SO activates 
MAPKs and that activation is dependent on cell type, which may in turn 
regulate differential functions in these different cell types.
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Background Not all rheumatoid arthritis (RA) patients respond well to 
the standard infliximab regimen. No clinical or biological factor that 
would allow one to predict response has yet been identified.
Objective The aim of the study was to test whether the -3 0 8  G/A 
polymorphism in the promoter of the TNF-a gene and the -1 0 8 2  G/A 
polymorphism in the promoter of the IL-10 gene influence response to 
infliximab therapy in patients with RA.
Methods We genotyped 85 RA patients for -308TNFalfa polymor­
phism by PCR and subdivided them into group A (A/A or A/G  geno­
types) and group B (G/G genotypes). We compared clinical response 
to infliximab treatment between the two groups after four infusions, 
using the DAS28 index.
Results We found that 47.4% of patients in group A and 79.3% of 
patients in group B had DAS28 index improvement greater than 1.2 
(P =0 .0075) and that the average DAS28 improvement was 1.12 in S23
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group A and 2.08 in group B (P =0 .05 ). IL-10 polymorphism did not 
allow us to discriminate between good and poor responders. 
Conclusion These data suggest that the -3 0 8  A/G  and the -3 0 8  A/A 
TNF-a genotypes predict poor response to infliximab therapy in RA. 
-308TNFalfa genotyping might represent an easy tool with which to 
predict response to infliximab treatment. Conversely, the IL-10 polymor­
phism did not appear to be useful.
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Background Gene array analyses reflect the molecular complexity in 
rheumatoid synovitis. Insufficient knowledge about the majority of differ­
entially regulated genes hampers adequate interpretation.
Objective To unravel this complexity, cell type specific expression pro­
files were applied as baseline information for comparison.
Methods Gene expression profiles were determined by Affymetrix HG- 
U133A array hybridization of synovial tissues, sorted blood monocytes, 
granulocytes, CD4 and CD8 T cells from up to 10 patients with 
rheumatoid arthritis (RA) and 10 normal donors (ND). Primary analysis 
was performed using MAS5.0. Tissues were scored according to histo­
logical standards (Krenn, Pathol Res Pract 2002).
Results Compared with ND synovium, 145 genes were differentially 
regulated in all, and up to 2681 genes in at least 50% of RA-ND pair­
wise comparisons. Marker genes of isolated cell populations were 
defined by absence in more than 70% of other populations and normal 
synovial tissue, defining 59, 25 or 110 genes for granulocytes, mono­
cytes or T cells, respectively. Of these markers, 1, 6 or 22 were identi­
fied in more than 50% of RA-ND comparisons for each cell type, 
respectively. This reflects the altered cellular composition in synovitis. 
Excluding all genes present in normal tissue or any of the purified popu­
lations revealed immunoglobulins as markers of B-cell infiltration. 
Conclusion This initial analysis of our approach substantially improved 
the quality of array interpretation and allows identification of tissue 
associated gene regulation. It helps to identify markers shared between 
blood and tissue and may provide candidates for disease classification 
and activity scoring.
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Background In Wegener's granulomatosis (WG) the development of a 
generalized vasculitis is based on strong expression of proteinase 3 
(PR3) on the surface of neutrophil granulocytes and the appearance of 
circulating high-affinity anti-PR3 autoantibodies (PR3-ANCAs) sug­
gesting an antigen-driven B lymphocyte maturation.
Objective In order to analyze mechanisms relevant to the induction of 
S24 ANCA, we compared the immunoglobulin heavy chain (VH) gene
F igure  1
CD20 staining of a cryosection from an endonasal Wegener 
granuloma.
repertoire in biopsy specimen of granulomas from two cases of ANCA­
negative localized W G  and from two cases of ANCA-positive general­
ized W G with a healthy control.
Methods Frozen tissue samples were stained for B lymphocytes by 
anti-CD20 APAAP. DNA was prepared, purified and subjected to a 
PCR with individual VH primers matching to the families VH1-VH6 and 
a JH consensus primer. After bacterial subcloning PCR products were 
sequenced and characterized for gene usage and mutational pattern. 
Results Immunohistology revealed lymphoid infiltrates within typical 
W G granulomas containing more than 30% B cells, which is sugges­
tive of germinal center formation (Fig. 1). One hundred and fifty differ­
ently rearranged VH genes from W G tissues were characterized and 
compared with 84 VH genes from peripheral blood of a healthy donor. 
The mutation frequency as well as the ratio of amino acid replacement 
to silent mutations indicate an antigen-driven selection of antibodies 
within such germinal center-like regions of the granuloma in W G and 
differ significantly from the healthy control. The VH genes in W G 
revealed both striking similarities to published PR3-ANCA-encoding 
genes as well as to VH genes from Staphylococcus aureus superanti­
gen-affine B cells. Furthermore, 50% of mutations within the binding- 
site coding regions led to negatively charged amino acids that favour 
affinity to the positively charged PR3.
Conclusion In W G a subset of autoreactive PR3-producing B cells 
may be induced to produce PR3-ANCA within granulomatous lesions 
after Staphylococcus aureus B-cell superantigen stimulation. Selected 
B cells undergo affinity maturation and differentiate into plasma cells 
that produce high levels of circulating ANCAs, which are involved in 
the pathogenesis of the systemic vasculitis.
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Introduction Toll-like receptors (TLRs) play an important role in the 
innate and adaptive immune response. TLR4 is the most thoroughly 
studied member of this receptor family and interacts with endogenous
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ligands, which are abundantly present in the synovial joint during 
rheumatoid arthritis (RA).
Objective The aim of the present study was to analyze the relationship 
between the TLR4 Asp299Gly (896A>G) polymorphism and RA suscepti­
bility, disease phenotype and outcome over a 6-year period of the disease. 
Methods Genotyping was performed on RA patients from an early RA 
inception cohort. Healthy controls consisted of healthy blood donors. 
To assess the influence of the TLR4 variant on disease phenotype, 
course and outcome, we compared prospectively collected disease 
activity and outcome parameters of patients with and without the 
variant TLR4 allele. TLR4 genotyping of the A>G polymorphism at 
position 896 of the TLR4 gene was performed using RFLP.
Results in 282 RA patients and 314 healthy individuals we found that 
the frequency of the TLR4 Asp299Gly polymorphism was significantly 
lower among RA patients (10.6%) than among controls (17.2%; 
P  =  0.02). To analyze potential differences in disease phenotype, 
severity and outcome 30 RA patients heterozygous for the TLR4 variant 
were compared with 252 RA patients possessing two wild-type alleles. 
Apart from the higher DAS at baseline (6.1 versus 5.4; P  =0 .01), no 
other differences in phenotype, severity or outcome of RA were 
detected between both groups.
D iscussion Here we demonstrate a link between RA disease suscepti­
bility and the TLR4 polymorphism in a large set of RA patients and 
healthy individuals. Furthermore, we show that the TLR4 polymorphism 
might be important in the onset of disease but does not seem to play a 
role in disease outcome.
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Background Sacroiliitis (SI) is a common extraintestinal manifestation 
of Crohn's disease (CD). In contrast to idiopathic ankylosing spondyli­
tis (AS), its association with HLA-B27 is less evident. Mutations in the 
CARD15 gene are recently identified as susceptiblity genes for CD. 
The CARD15 gene encodes the intracellular NOD2 receptor and 
should play an important role in innate immunity. Studies on associated 
disease phenotypes revealed a predisposition for ileal localization, early 
onset of disease, familial cases and fibrostenosing disease. We 
recently described a higher prevalence of CARD15 variants in a sub­
group of spondyloarthropathy patients with chronic gut inflammation, 
which are prone to evolution to CD.
Background The present study evaluated whether CARD15 polymor­
phisms are associated with sacroiliitis in patients with CD.
Methods One hundred and two consecutive CD patients were clini­
cally evaluated by a rheumatologist. Radiographs of sacroiliac joints 
were performed and blindly scored by two investigators. RFLP-PCR 
technique was used to genotype all patients for three single nucleotide 
polymorphisms in the CARD15 gene. Every SNP was verified by direct 
sequencing. HLA-B27 phenotype was determined.
Results Radiological evidence of SI with or without AS was present in 
23 patients (23%). Of patients with SI 78% carried a CARD15 variant, 
versus 48% of patients without SI (P = 0 .01 1 ; OR 3.8, 95% CI 
1.3-11.5). A logistic regression analysis with SI as dependent variable 
and CARD15, HLA-B27, famililial cases, need for resection surgery, 
age of diagnosis and ileal disease as covariates showed that only car­
riage of CARD15 variants was a significant predictor of SI (P =  0.035). 
Conclusion This result suggests that carriage of CARD15 variants is a 
genetic marker for CD related SI, independent of HLA-B27 or other 
CARD15 related phenotypes.
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The molecular pathogenesis of rheumatoid arthritis (RA) is still poorly 
understood and its clinical course can vary widely. In a recent report 
we noted heterogeneity in global gene expression signatures between 
synovial tissue specimens from different patients with RA. The results 
of the present study support the view that clinically diagnosed RA is a 
heterogeneous disease that is featured not only at the whole synovial 
tissue level but also at the level of FLS cultured from those tissues. 
One of the most impressive features of our 24k cDNA microarray profil­
ing studies is the clear correlation of the FLS phenotype with that of 
paired synovial tissue from which the cells were derived. One class of 
FLS is tightly related to the presence of lymphocytes in the lesions 
whereas the other class of FLS suggests that synoviocyte-mediated 
invasion appears to be less dependent on infiltrating immune cells. 
Clearly, the list of genes that are differentially expressed between the 
FLS subgroups facilitates our understanding of the pathophysiology of 
the distinct groups of rheumatoid FLS. These data reveal features of 
fibrosis as the hallmark of FLS derived from a high inflammatory lesion, 
whereas FLS that are characterized by deregulated growth appear to 
constitute a characteristic feature of low inflammatory tissues. These 
data support the notion that heterogeneity between synovial tissues is 
reflected in the FLS as a stable trait and provide a molecular basis for 
the well recognized but as yet poorly understood heterogeneity in RA.
Gene therapy
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Background Salivary glands (SGs) provide a novel target site at which 
gene transfer can be accomplished in a minimally invasive manner [1]. 
SGs are also capable of producing large amounts of proteins, and 
human SGs are well encapsulated, a circumstance likely to minimize 
the undesirable access of administered vectors and transgenes to 
other tissues [2]. Previous studies have indicated that intravenous, 
intramuscular and intranasal administration of rAAV2 vectors induce 
relatively mild host immune responses.
Objective The aim of the study was to examine the effects on immune 
responsiveness of rAAV2 vector delivery into SGs.
Methods The main excretory ducts of the submandibular glands of 
Balb/c mice were cannulated and vectors administered by retrograde S25
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infusion [1]. On day 0 we delivered a rAAV2 encoding p-galactosidase 
or saline (control) to adult mice. On day 28, we administered a second 
rAAV2 vector encoding either human erythropoeitin (Epo) or human 
growth hormone to one-third of each group. Immune activities were eval­
uated in saliva, serum, SGs and spleens collected at different times. 
Results Vector delivery had little effect on salivary flow rates at all time 
points studied. Histological examination of SGs on day 1 did not indi­
cate any significant inflammatory cell infiltration due to rAAV2 vectors. 
Ex vivo stimulation, with rAAV2, of splenocytes on days 28 and 56 
resulted in elevated interferon-y levels in culture media from rAAV2- 
administered mice, but not from control mice. Significant titers of neu­
tralizing antibodies to rAAV2 were detected in serum, with generally 
lower levels found in saliva. We were unable to observe transduction of 
SG cells by rAAV2Epo in mice previously infected with rAAV2LacZ (i.e. 
no elevations in hematocrit [Hct] and serum Epo levels were seen in the 
virus re-administration group). Conversely, we found significant eleva­
tions in Hct and serum Epo levels in mice previously administered saline. 
Conclusion We conclude that after a single administration of rAAV2 to 
murine SGs there is no significant innate immune response. However, 
we observe a modest adaptive immune response that abrogates the 
efficacy of additional rAAV2administration.
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Objective Adeno-associated virus (AAV) is a very promising vector for 
gene therapy in RA. Although an increasing number of AAV serotypes 
have been identified, all studies so far have been performed with 
serotype 2. The aim of this study was to compare the transduction effi­
ciency of five different AAV serotypes (AAV1-AAV5) encoding reporter 
genes, the murine secreted alkaline phosphatase (mSEAP) or the 
E. coli p-galactosidase (beta-Gal), in two different animal models of 
arthritis.
Methods AAV1-AAV5 containing the gene for beta-Gal were injected 
into the right ankle joints of rats with adjuvant arthritis (AA) on day 12 
after adjuvant immunization. Joints were collected 2 weeks after injec­
tion. The number of viral genomic copies in the joint was determined by 
qPCR. For detection of LacZ transcription in joints and organs, 
RT-PCR was used. Beta-Gal expression was analyzed by direct in situ 
staining of frozen sections, quantified by digital image analysis. In mice 
with collagen-induced arthritis (CIA), AAV1, 2 and 5 constructs encod­
ing the mSEAP gene were injected into the left knee joint 32 days fol­
lowing arthritis induction. Transgene expression was analyzed by 
chemiluminescence in sera and culture medium conditioned by the 
joint tissues at different time points.
Results The greatest number of viral genomic copies was detected 
using AAV5. This was confirmed by in situ beta-Gal staining. RT-PCR 
proved the presence of LacZ mRNA in injected joints, but not in any of 
the organs tested. In the CIA mice model AAV5 also had the best 
S26 transduction efficiency. Transgene expression was detectable in sera
and patellae 1 week after joint injection, increased over time, and 
remained at plateau levels for at least 1 month.
Conclusion In vivo gene transfer with AAV5 is far more efficient than 
with other serotypes. Local AAV-mediated gene therapy in RA could be 
improved by using AAV5.
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Background Rheumatoid arthritis is characterized by an acute phase 
response of the liver. IL-6 is produced in the inflamed joint and high levels 
are found in the circulation. IL-6 is a potent inducer of acute-phase pro­
teins (APP) in hepatocytes via its signal transducer gp130 by the activa­
tion of the signal transducer and activator of transcription (STAT)-3. 
Objective The aim of the study was to determine the effect of adenovi­
ral gene transfer of SOCS-3, the inhibitor of STAT3 activation, on colla­
gen-induced arthritis (CIA).
Methods Livers were dissected, and activation of STATs was analyzed 
by Western blot and gene expression by RT-PCR. A replication incom­
petent adenovirus containing the gene of murine SOCS-3 was con­
structed. Mice received 3 x  10e8 ffu of Ad5.CMV.mSOCS3 or control 
viruses intravenously before onset of arthritis. The effect of SOCS gene 
transfer on liver function was studied in zymosan-induced gonarthritis 
(ZIA) and the therapeutic effect in CIA.
Results Induction of ZIA in the knee joints of mice caused a rapid 
(within 5 hours) activation of STAT3 but not STAT1 in the liver. The 
activation of STAT3 was IL-6 dependent, as shown using IL-6 gene 
knockout mice. Intravenous injection of Ad5.CMV.mSOCS3 24 hours 
before induction of ZIA prevented STAT3 activation and markedly 
reduced serum amyloid A (SAA)-1 gene expression in the liver. Control 
virus treatment did not inhibit STAT3 activation in the liver. Overexpres­
sion of SOCS-3 did not affect Erk activation, confirming selectivity for 
the STAT signaling pathway. Treatment of DBA1/j mice with 
Ad5.CMV.mSOCS3 virus after immunization ameliorated CIA, and 
reduced serum TNF-a levels accompanied this effect. SOCS-3 treat­
ment had no effect on the circulating levels of total IgG, IgG2a and IgG1 
anti-collagen type II antibodies.
Conclusion Inhibition of STAT-mediated signaling via SOCS-3 adenovi­
ral gene transfer in the liver markedly ameliorated CIA. This suggests that 
the IL-6 mediated liver response modulates the development of arthritis.
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Background and Objective Novel cytokines have been identified by 
structural homology to IL-10. Among them, IL-22 showed a 25% amino 
acid identity with IL-10 and shared a common receptor p-subunit. The 
expression profile suggested involvement in the immune response in 
vivo. The present work evaluates the role of IL-22 in arthritis, examining 
the effects of systemic murine IL-22 adenoviral-mediated overexpression 
(Ad-mIL-22) in the collagen-induced arthritis (CIA) DBA1 mouse model.
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Method H uman rheumatoid arthritis (RA) synovial fibroblast (SF) were 
infected in vitro with increasing doses of Ad-mIL-22 (0-25 MOI). 
Cytokine secretion was assessed in supernatant using a specific 
ELISA. Therapeutic efficiency of mIL-22 overexpression achieved by 
intravenous injection of Ad-mIL22 (5 x  109 pfu) after the onset of CIA 
was assessed. A group injected with a nonrelevant adenoviral vector 
(Ad-LacZ) was used as a control. Radiological and histological analy­
ses were performed at day47. Systemic expression of mIL-22 was 
assessed by ELISA.
Results After confirmation that human RA-SF infected with increasing 
doses of Ad-mIL-22 expressed high levels of mIL-22 transgene, we 
demonstrated that the intravenous injection of Ad-mIL-22 in DBA1 
mice significantly reduced clinical, radiological and histological scores. 
By the end of the experiment, the number of arthritic paws was 
decreased by 70% in the Ad-mIL-22-treated group as compared with 
controls (P <0,0001). Ad-mIL-22 resulted in the complete protection 
as compared with control vector up to 20 days after treatment. Maximal 
paw widths reached during the course of the disease were, respec­
tively, 1.95 x  0.08 versus 2.76 x  0.60 mm (P =0 .024). Both radiologi­
cal and histological scores were found to correlate well with clinical 
observations. Systemic levels of mIL-22 reached 14.2 ±  9.5 ng/ml
4 days after gene transfer, then decreased to 2.4 ±  0.9 ng/ml by day 8 
and remained stable until day 21.
Conclusion Our data support that IL-22 may have antiarthritic proper­
ties. The molecular mechanisms responsible for this observation are 
under investigation.
82
Nonviral gene therapy by electrotransfer of hTNF-a 
soluble receptor variants: application to the 
treatment of collagen arthritis
C B loque !1, P B igey2, D Scherm an2, MC B o iss ie r1, N Bessis1
1UPRES EA-3408 and Rheumatology Department, University Paris 13 
and Avicenne Hospital (AP-HP), Bobigny, France; 2U266 ¡NSERM 
FRE 2463 CNRS, Faculté de Pharmacie, Paris, France 
Arthritis Res Ther 2004 6(Suppl 1):82 (DOI 10.1186/ar1124) 
Objectives Electrotransfer (ET) was used to administer transgenes 
encoding three hTNF-a soluble receptor-I variants. Electrotransfer 
parameters and therapeutic effect in collagen-induced arthritis (CIA) in 
mice were studied.
Methods Plasmids pCOR(hTNFRIs)1, pCORhTNFRIs/mIgG1, 
pCOR(hTNFRIs)2, encoding a monomeric, a chimeric or a dimeric form 
of hTNFRI, respectively, were used. Electrotransfer was performed by 
plasmids injection and electric pulses in muscle. hTNFRIs concentra­
tions were determined by ELISA. PCR was performed on genomic 
DNA from various mouse organs to detect the plasmid. CIA was 
induced by immunization of DBA/1 mice with collagen II in adjuvant. 
Results ET of the three plasmids (1 -15  ^g) allowed hTNFRI produc­
tion in sera and muscle after 10 days. This expression was dependent 
on the dose of plasmid. Local expression in the muscle lasted for at 
least 6 months. Systemic expression in the serum was detectable right 
from 1 ^g for the hTNFRIs/mIgG1 form. It lasted for at least 6 months 
for the hTNFRIs/mIgG1 form, whereas expression was shorter for the 
two other forms (3weeks). No plasmid DNA was found in the organs 
distant from the injected muscle (liver, spleen, kidney, gonads, heart, 
lung brain and distant muscle). ET of 50 ^g  pCOR/sTNFRI/IgG1 
plasmid at the onset of clinical disease induced a clear-cut decrease in 
clinical signs of arthritis. The dimeric form was also efficient 
(P = 0 .0378) although the effect was weaker than with the fusion 
protein. The monomeric form had no effect on arthritides.
Conclusion Intramuscular ET of plasmids encoding the three forms of 
hTNFRIs leads to a long-term secretion of hTNFRIs in vivo. CIA is effi­
ciently inhibited when ET of plasmids encoding either the chimera or 
the dimeric hTNFRIs was performed at the onset of the disease.
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B ackground Gene therapy studies in experimental models of arthri­
tis have demonstrated effective treatment with a variety of immuno- 
suppresive and proapoptotic genes using in vivo and ex vivo 
strategies. Regardless of which approaches are developed for clini­
cal application of gene therapy, we believe that it is imperative that 
expression of a therapeutic gene is regulated so that levels of 
expression are controlled and can be downregulated in the event of 
adverse effects.
Objective We previously constructed an autoregulatory self-contained 
plasmid vector pGTRTL in which gene expression is induced with doxy- 
cycline (Dox). Expression kinetics of luciferase from this vector have 
been characterized in vitro. In this investigation we examined the 
dynamics of luciferase expression from pGTRTL delivered in vivo to 
DBA/1 mice. Therapeutic effect of a small dimeric TNFR2 molecule 
(dTNFR) expressed constitutively from the vector pcdTNFR and regu­
lated from the vector pGTRTT was compared in DBA/1 mice with 
established collagen-induced arthritis (CIA).
Methods Plasmid DNA was administered to naïve or arthritic mice by 
intramuscular injection combined with electroporation. Gene expres­
sion from regulated vectors was induced with Dox administered in 
drinking water. The degree of arthritis was scored every 2 -3  days, and 
at the end of the experiment serum immunoglobulin levels and cytokine 
release from lymph node cells was measured.
Results The results show efficient regulation of luciferase expression 
from pGTRTL in vivo. Expression of dTNFR from constitutive or regu­
lated expression vectors in mice with established CIA was therapeutic 
(Fig. 1), but was dependent upon the level of disease activity when 
treatment was initiated.
F igu re  1
Progression of CIA in mice treated with dTNFR expressed 
constitutively from pcdTNFR (a) and induced from pGTRTT (b).
Conclusion Improved pharmacologically regulated vectors could be 
developed for clinical application. There is also scope to utilize disease- 
responsive vectors that contain DNA binding motifs that respond to 
transcription factors upregulated in arthritic joints.
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Objectives We performed here a detailed analysis of the newly devel­
oping immune systems in patients treated with immune ablation and 
subsequent autologous stem cell transplantation (ASCT) for severe 
autoimmune diseases.
Methods Peripheral blood lymphocytes were analyzed using flow 
cytometry, including assessment of TCR-VP repertoire of Th cells. 
Thymic activity was determined by measuring T-cell receptor excision 
circles (TRECs) in distinct peripheral blood Th cell subsets by quantita­
tive RT-PCR analysis.
Results Twelve patients, with median follow up of 40 months, were 
included in the trial thus far: polychonditis (n =  1), systemic lupus ery­
thematosus (SLE; n =  6), systemic sclerosis (SSc; n =  3), panniculitis 
(n =  1) and MS (n =  1). Clinical remission has been achieved in seven 
patients: polychondritis (n = 1 ), SLE (n =  5) and MS (n = 1 ). We 
observed progress of disease in patients with SSc and panniculitis. In 
one patient SLE reactivated 17 months after ASCT. In all responding 
patients no autoreactive Th cells could be detected, and serological 
remission has been achieved. Lymphocyte compartments reconstituted 
functionally in all patients as shown by the reappearance and persis­
tence of naïve T cells with high levels of TRECs and restored diversity 
of the T cell receptor repertoire. Reconstituting B cells were found to 
be of naïve phenotype. Although we observed similar kinetics of lym­
phocyte repopulation in the nonresponding SSc patients, autoantibody 
titres (ANA, SCL70) were not affected by conditioning.
Conclusion The newly generated immune system in responding 
patients is tolerant to rheumatic autoantigens and able to react to 
pathogens. We conclude that in successfully treated patients autore­
active memory and effector lymphocytes have been eliminated effi­
ciently. Our data demonstrate that ASCT can induce stable long-term 
clinical and serological remission in patients with severe, standard- 
therapy refractory autoimmune diseases.
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Objective Increased osteoclast activity is a key factor for bone loss in 
rheumatoid arthritis (RA). This suggests that osteoclast-targeted thera­
pies could effectively prevent skeletal damage in RA. Zoledronic acid 
(ZA) is one of the most potent agents to block osteoclast function. We 
therefore investigated whether ZA can inhibit inflammatory bone loss. 
Methods Human TNF transgenic (hTNFtg) mice, which develop severe 
destructive arthritis as well as osteoporosis, were treated with phos­
phate-buffered saline, single or repeated doses of ZA, calcitonin or 
anti-TNF at the onset of arthritis.
Results Synovial inflammation was not affected by ZA. In contrast, 
S28 bone erosion was retarded by single administration (-60% ) and almost
completely blocked by repeated administration (-95% ) of ZA. Carti­
lage damage was partly inhibited (-40% ), and synovial osteoclast 
counts were significantly reduced upon ZA treatment. Systemic bone 
mass dramatically increased in hTNFtg mice upon ZA administration, 
which was due to an increase of trabecular number and connectivity. In 
addition, bone resorption parameters were significantly lowered after 
ZA. Calcitonin had no effect on synovial inflammation, bone erosions, 
cartilage damage, or systemic bone mass. Anti-TNF entirely blocked 
synovial inflammation, bone erosion, synovial osteoclast formation and 
cartilage damage, but had only minor effects on systemic bone mass. 
Conclusion ZA appears an effective tool with which to protect bone 
from arthritic damage. In addition to anti-inflammatory drug therapy, 
modern bisphosphonates are promising candidates to maintain joint 
integrity and to reverse systemic bone loss in arthritis.
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Background Effective amelioration of symptoms and induction of 
remission are goals in treatment of rheumatoid arthritis (RA).
Objectives Data from a Phase II study for RA treatment with abatacept, 
a selective co-stimulation modulator, showing induction of remission 
(DAS-28 score <2 .6) are presented.
Methods Patients on background methotrexate (MTX) who met ACR 
criteria for active RA with > 10 swollen joints (66 joint count) and 
> 12 tender joints (68 joint count) were randomly assigned to receive 
1 0 mg/kg abatacept (n = 1 1 5 )  or placebo (n = 1 1 9 ) treatment for 
1 year. DAS-28 scores and serum cytokine levels were assessed at 
days 1, 90, 180 and 360.
Results Abatacept-treated patients showed a progressive increase in 
remission rates up to 1 year (analysis not prespecified) compared with 
placebo (P <  0.001; Fig. 1). Abatacept treatment also decreased serum 
levels of proinflammatory cytokines. In particular, levels of serum IL-6, a 
multifunctional cytokine that contributes both to acute phase response 
and to pathological B cell activation, were reduced by 67% at 180 days 
and by 73% at 360 days (P <0 .05). Placebo-treated patients showed 
no reduction. Abatacept was generally safe and well tolerated.
F igure  1
Abatacept increases the remission rate in RA patients refractory to 
MTX treatment. Means and 95% confidence intervals are shown.
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Conclusions In patients with active RA who were receiving MTX, abat- 
acept treatment significantly improved RA symptoms and produced a 
progressive increase in remission rates for over one-third of the treat­
ment group, which was sustained at 1 year. In addition, abatacept 
decreased serum IL-6 levels. The results of this phase II study suggest 
that abatacept may have potential as therapy for patients with active 
RA despite MTX treatment.
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Background Upregulation of drug efflux pumps belonging to the family 
of ATP-binding cassette (ABC) transporters can confer loss of effi­
cacy/resistance to muliple cytostatic drugs, a phenotype referred to as 
multidrug resistance (MDR). In clinical rheumatology practice, loss of 
efficacy of disease-modifying antirheumatic drugs (DMARDs) is 
observed following long-term treatment of rheumatoid arthritis (RA) 
patients. Whether loss of efficacy/resistance to DMARDs and cytosta­
tic drugs share common molecular mechanisms is not known. 
Objective The aim of this study was to delineate the potential role of 
MDR proteins in the loss of efficacy/resistance to DMARDs.
Methods In vitro model systems of human T cells and monocytic/ 
macrophage cell lines were used to provoke resistance to the DMARD 
sulfasalazine (SSZ). SSZ-resistant cell lines, as well as macrophages 
from RA patients and healthy controls, were characterized for expres­
sion of MDR proteins.
Results Development of SSZ resistance in T cells and monocytic/ 
macrophage cell lines was accompanied by a marked induction of the 
MDR protein ABCG2. Of note, SSZ-resistant cells displayed cross­
resistance to methotrexate, but showed enhanced sensitivity to gluco­
corticoids (prednisone, dexamethasone). Immunohistochemical studies 
revealed increased expression of MDR proteins in macrophages from 
RA patients as compared with controls.
Conclusion These results suggest that MDR proteins, originally identi­
fied for their role in resistance to cytostatic drugs, could also be involved 
in DMARD resistance [1]. Beyond this, resistance to one particular 
DMARD can influence the sensitivity to other antirheumatic drugs. 
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According to the current view, chronic AID are driven by the continu­
ous activation of autoreactive B and T lymphocytes. However, despite 
the use of potent immunosuppressive drugs, these patients exhibit con­
tinued autoantibody production, which often contributes to progression
of the AID. To elucidate this problem, we analyzed the lifespan of cells 
secreting (auto)antibodies (Ab) in NZB/W  mice. The number of 
Ab-secreting cells in splenic tissue increased from ages 1 to 5 months 
and became stable thereafter. Later, some 60% of the total Ab-secret­
ing cell compartment consisted of dividing, short-lived plasmablasts 
(SLPB), whereas 40% consisted of nondividing, long-lived plasma cells 
(LLPC) with a half-life of more than 6 months. Although high-dose 
cyclophosphamide eliminated SLPB, LLPC survived and continued to 
produce (auto)Ab. This explains why treatment with cyclophosphamide 
(CY) does not result in the complete disappearance of antinuclear Ab. 
Pathogenic anti-dsDNA Ab usually vanish after this treatment, indicat­
ing that they are generated by proliferating SLPB. However, anti­
dsDNA Ab can be resistant to CY in refractory SLE.
We treated six refractory SLE patients by autologous stem cell trans­
plantation (ASCT) using CY and ATG as the mobilization regimen. 
ASCT was performed using purified CD34+ stem cells. The patients 
have now been followed for 5 -7 0  months. Initially, persistent anti­
dsDNA disappeared within 3 months. Likewise, the ANA became nega­
tive except in one case. That patient continued to exhibit anti-Ro/SSA 
and anti-La/SSB, the titers of which decreased continuously and were 
undetectable after 17 months. This emphasizes the enormous lifespan 
of residual plasma cells after interrupting the supply of new cells from 
the dividing SLPB compartment.
In conclusion, the aforementioned ASCT protocol can lead to depletion 
of autoreactive LLPC. Since ASCT may not always be able to eliminate 
autoreactive LLPC, these cells are potential targets for autoimmune 
disease therapy.
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Addition of cyclosporine-A (Neoral®) in patients on 
anti-TNF and methotrexate therapy improves disease 
activity: an open-label, pilot study
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University of Crete, Heraklion, Greece
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Background Combining anticytokine treatment with a T-cell directed 
agent such as cyclosporine A (CsA) may rescue patients refractory to 
anti-TNF treatment. We performed an open label, pilot study to explore 
the safety and initial efficacy of a triple therapeutic regimen with anti- 
TNF, methotrexate (MTX) and CsA.
Methods Nineteen patients with treatment-resistant RA have been 
enrolled. Patients had considerable residual disease activity (mean 
DAS-28 6.8, 4.5-8.6), although they had received a mean of 
16.8 infliximab infusions (range 6 -23 ) and adequate dose adjustments 
of both infliximab (mean dose 4.2 mg/kg q6w) and MTX (mean dose 
17.1 mg/week). CsA (mean dose of 2.7 mg/kg per day, range 1.6-3.2) 
was added to a stable therapeutic regimen. Clinical evaluation of 
disease activity and treatment side effects was performed before each 
infliximab infusion. Disease activity was evaluated according to DAS-28 
index. Primary end-points were treatment safety profile and efficacy 
according to the EULAR response criteria. Peripheral blood monocytes 
(PBMCs) were collected from five patients at baseline and after 
12 weeks, and were assessed for markers of activation (CD25 expres­
sion) by FACS analysis, with or without activation with PHA.
Results Sixteen patients completed 12 weeks of triple therapy. Three 
patients discontinued treatment because of adverse events: one for 
pneumonia, one for lymph node tuberculosis and one for gastrointesti­
nal discomfort. Seven out of 16 patients (43.7%) achieved moderate 
response according to the EULAR response criteria. Statistically signif­
icant improvements in the mean values of tender joints (from 18.5 to 
13.1; P  =0 .04 ), swollen joints (from 18.6 to 12.1; P  =0 .004), HAQ 
(from 1.2 to 0.7; P  =  0.01), patients' global assessment (from 67 to 46; 
P  = 0 .02 ) and pain (from 64 to 42; P  = 0 .04 ) were identified in those 
16 patients. CD25 expression both in unstimulated and in PHA stimu­
lated PBMCs was reduced (37 ±  34% to 15 ±  10%, and 50 ±  15% to 
29 ±  20%, respectively). S29
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Conclusion In this preliminary report, addition of CsA to a maximum 
combination therapy of anti-TNF and MTX was well tolerated. Infectious 
complications that occurred underscore the importance of close follow 
up of patients on combined immunosuppressive therapy. Longer follow 
up is required to investigate further the safety and initial efficacy of this 
regimen.
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Effects of anti-TNF therapy on endothelial function 
and intima-media thickness of common carotid 
artery in patients with rheumatoid arthritis
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Background TNF has been reported to decrease endothelium depen­
dent vasodilatation and promote atherosclerosis. However, recent data 
suggest that TNF may also increase the production of nitric oxide 
(NOx) by blood vessels, suggesting a more complex effect of this 
cytokine. To explore this further, we examined the effect of anti-TNF 
agents on flow-mediated vasodilatation (FMD) as well as common 
carotid intima-media thickness (IMT) in RA patients.
Methods Two groups of rheumatoid arthritis (RA) patients were 
studied. In the first, six patients were treated for the first time with a 
triple DMARD combination (methotrexate, hydroxychloroquine and sul- 
phasalazine) because of highly active disease (mean DAS-28 6.1). In 
the second group 12 patients with active disease (mean DAS-28 6.1), 
despite treatment with DMARDs (methotrexate or leflunomide with or 
without corticosteroids), were started on anti-TNF agents. Patients 
were assessed by high-resolution ultrasound for CC-IMT, FMD (per­
centage of increase in flow-mediated vasodilatation) of the brachial 
artery at baseline and after 12 weeks of treatment. RA disease activity 
was assessed using the DAS-28, ESR and CRP at the same time 
points. Based on the DAS-28, patients were classified as good, moder­
ate or nonresponders. Plasma NOx levels will be measured by the mod­
ified Griess reaction.
Results Two patients in the first group (33%) and six in the second 
(50%) had a moderate EULAR response. In both groups moderate 
improvements in the mean ESR (from 60 ±  39 to 50 ±  27 and from 
38 ±  19 to 34 ±  24, respectively) and CRP (from 1.3 ±  1.3 to 1 ±  0.3 
and from 3.7 ±  3.7 to 2.3 ±  2.8, respectively) were found, which were 
not significant. Although FMD tended to improve in patients in the first 
group (from 9.2 ±6 .4%  to 12.3 ±4 .9% ; P  = 0 .11 ) between baseline 
and week 1 2, patients in the second group remained stable (from 
9.5 ± 7 .2  to 7.9 ± 5 .4 ; P  =0 .49). CC-IMT increased by 6.4% 
(0.76 mm to 0.80 mm) in the first group whereas it decreased by 3% 
(from 0.65 mm to 0.63 mm) in patients on anti-TNF agents. The effect 
on CC-IMT was even greater (from 0.61-mm to 0.53-mm; P  = 0 .08 ) in 
patients on anti-TNF agents and absence of other risk factors for ather­
osclerosis (e.g. obesity, hypertension or hyperlipidemia). Measurement 
of plasma NOx levels is in progress.
Conclusions In this pilot study in patients with highly active RA, mod­
erate improvement in disease activity after anti-TNF therapy did not uni­
formly improve FMD. This may reflect suboptimal control of disease 
activity or decrease in TNF-dependent NO production.
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Background In patients with rheumatoid arthritis (RA), inflammation, 
dysregulated Epstein-Barr virus (EBV) infection and immunosuppres­
sive therapy may contribute to increased risk for developing lymphoma. 
We have shown that EBV load in peripheral blood mononuclear cells 
(PBLs) is 10-fold higher in RA patients (16 copies/500 ng DNA) than 
in normal controls (1.9 copies/500 ng DNA). EBV load in RA patients 
is similar to that in healthy transplant recipients and much lower than in 
symptomatic EBV-infected transplant recipients with lymphoprolifera- 
tive disease (>500 copies/500 ng DNA).
Objectives We monitored EBV load in RA patients' PBLs to evaluate 
how it was influenced by methotrexate and infliximab, and to detect 
lymphoma development.
Methods A total of 221 patients fulfilling the 1987 ACR criteria for RA 
and 100 healthy controls were studied. Of these 221 patients, 88 were 
followed for 1 -4  years: 19 received only methotrexate (eight were 
included in the study before introduction of methotrexate), eight received 
only infliximab, and 61 received both methotrexate and infliximab. A 214 
base-pair fragment from the EBV genome first internal repeat (IR1) was 
amplified by quantitative real-time PCR to evaluate EBV DNA load. 
Results EBV load decreased dramatically in most patients right after intro­
duction of methotrexate and kept decreasing thereafter. In patients receiv­
ing infliximab and methotrexate, three patterns of EBV load evolution were 
observed: stable, decreasing and variable. Patients with only infliximab had 
either stable or decreasing EBV loads. Although an increase in EBV load 
was observed in a few patients, none of them reached the 
500 copies/500 ng level and no patient developed lymphoma. 
Conclusions Methotrexate and infliximab do not seem to increase EBV 
load in patients with RA.
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Objective The aim of the study was to determine whether a new 
method, based on intrapatient comparisons between estimated rates of 
prediagnosis radiological progression and subsequent progression, 
can be used to assess the efficacy of commonly used disease-modify­
ing antirheumatic drugs (DMARDs) in a longitudinal early rheumatoid 
arthritis (RA) inception cohort.
Methods We analyzed clinical data and radiographs from 149 newly 
diagnosed RA patients. Four groups were chosen: patients treated 
with methotrexate (MTX, n =  56), sulfasalazine (SSZ, n =  55) and aura- 
nofin (AUR, n =  19), and a control group of patients who had changed 
therapy twice during the first 2 years after diagnosis and whom we pre­
viously presented as a group of poor responders with persistent clinical 
activity (control, n = 1 9 ). Radiographs were quantified by an experi­
enced reader using Larsen Erosion Score and the ‘X-RayRheuma- 
Coach' software. The rate of prediagnosis radiological progression per 
time was estimated by taking the first onset of RA symptoms as the 
starting date for radiographic damage.
Available online http://arthritis-research.c0m/supplements/6/S I
Results The mean disease duration from onset of symptoms until diag­
nosis and DMARD institution was 6.7 ±  3.6 months. The mean baseline 
Larsen Score was 13.2 ±  9.3, resulting in an estimated prediagnosis 
progression rate of 23.6 ±  16.7 Larsen Score units/year. In the control 
group and in the patients receiving AUR, radiological progression after 
diagnosis was similar to the predicted progression based on the esti­
mated prediagnosis progression rates. In patients for whom MTX or 
SSZ was the first-line therapy, a marked (P < 0 .001 ) reduction in radi­
ographic progression in the first year after treatment initiation was seen 
compared with prediagnosis progression.
Conclusions Prediagnosis rates of radiological progression can be 
used quantitatively to obtain important information on the potential effi­
cacy of DMARDs, and indicate that MTX and SSZ, but not AUR, signif­
icantly retard radiographic damage in the first year after diagnosis.
93
The effect of infliximab on skin lesions in a patient 
with scleroderma (CREST)
L De Rycke, D Baeten, F Van den Bosch, H M ie lants, 
F De Keyser, EM Veys
Rheumatology, Ghent University Hospital, Belgium 
Arthritis Res Ther 2004 6(Suppl 1):93 (DOI 10.1186/ar1135) 
Background Skin lesions refractory to treatment are a source of mor­
bidity in patients with scleroderma (CREST) and may result in amputa­
tion. No established DMARD is available for this disorder.
Objective The aim was to report the effect of infliximab in combination 
with methotrexate (MTX) on refractory skin lesions in a 46-year-old 
woman with scleroderma (CREST).
Case report In 1991, the patient was diagnosed with scleroderma 
(CREST). Despite several treatments (initially D-penicillamine and 
colchicine, subsequently MTX, colchicine and misoprostol), she devel­
oped severe digital ulcerations, resulting in multiple amputations with 
difficult wound healing afterward. Since 1999, she was treated with 
MTX, colchicine and alprostadil. In August 2002 she developed necro­
sis at the fingertip of digit IV right. Despite hyperbaric oxygen treatment 
and pulse therapy with corticosteroids, the necrosis worsened. There­
fore, infliximab (3 mg/kg iv at weeks 0, 2 and 6, and every 8 weeks 
thereafter) combined with MTX (10 mg/w im) was started. The patient 
also had ulcerations at digit II left and at the knees, and suffered from 
severe Raynaud's attacks. After the second infusion, the ulcerations 
started to heal. Although an amputation of distal phalanx of digit IV 
could not be avoided, infliximab was continued. The amputation wound 
healed quickly, the ulcerations became considerably smaller, and she 
developed no new skin lesions. The inflammatory parameters remained 
stable and her general condition improved; she gained weight (6 kg), 
had less pain in the fingers and fewer Raynaud's attacks, and her skin 
became more supple. Infliximab was stopped after eight infusions. 
Now, 4 months later, the previous ulcerations remain healed, no new 
digital lesions occurred and the inflammatory parameters are stable. 
Conclusion We present a patient with scleroderma (CREST) and 
refractory skin lesions. Infliximab combined with MTX was well toler­
ated and effective in the healing of ulcerative lesions.
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Anti-TNF-a antibody Infliximab and glucocorticoids 
reduce serum vascular endothelial growth factor 
(VEGF) levels in patients with rheumatoid arthritis: 
a pilot study
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Background Pannus growth in rheumatoid arthritis (RA) is critically 
dependent upon accompanying neovascularization. Vascular endothelial
growth factor (VEGF) is a potent angiogenic promoter, which is thought to 
play a crucial role in synovial angiogenesis in rheumatoid arthritis (RA).
Serum VEGF levels are elevated in RA patients, and therapy with the anti- 
TNF-a antibody infliximab reduces serum VEGF levels in these patients.
Objective The study was conducted to compare the early effect of oral 
glucocorticoids (GC) with anti-TNF-a therapy (infliximab) on serum 
VEGF levels in patients with RA.
Methods Five RA patients (5/8) who had no prior treatment with 
DMARDs or glucocorticoids (GC) were administered 20 mg/day pred­
nisolone. Three patients who failed more than one disease-modifying 
antirheumatic drug (DMARD) therapy received infusion with infliximab 
(200 mg). VEGF serum levels were measured using ELISA before 
treatment and at day 10 or 13 during prednisolone therapy or 14 days 
after the first infliximab infusion.
Results Serum VEGF levels in therapy naïve RA patients (GC group) 
were higher than those in pretreated patients who received infliximab 
(median serum VEGF level: 1106pg/m l versus 320pg/m l; P  =0,09). 
Treatment with infliximab as well as glucocorticoids significantly 
decreased serum VEGF levels after 10 -14  days in RA patients (median 
serum VEGF level after treatment: GC group 559 pg/ml, infliximab 
group 92 pg/ml; P  =  0.01 versus without treatment or preinfusion).
Conclusions Treatment with oral glucocorticoids leads to an early and 
drastic reduction in serum VEGF levels in therapy naïve RA patients.
TNF-a inhibition by infliximab could reduce low serum VEGF levels in 
pretreated RA patients independent of the initial serum VEGF concen­
tration. This is the first report comparing the effect of both therapies on 
serum VEGF levels, indicating a possible therapeutic inhibition of 
angiogenesis in RA.
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Allogeneic bone marrow transplantation can 
suppress established and otherwise chronic 
collagen-induced arthritis after a nonmyeloablative 
conditioning regimen employing anti-CD40 ligand 
monoclonal antibody
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Objective Allogeneic bone marrow transplantation (BMT) may be more 
effective than autologous BMT as a treatment for patients with severe 
autoimmune diseases, such as rheumatoid arthritis (RA). However, the 
application of allogeneic BMT for treatment of RA is not yet feasible 
because of the high-dose immunosuppression that is used before and 
after BMT. Therefore, in this study collagen-induced arthritis (CIA) -  the 
classic mouse model for RA -  was used to compare the effects of allo­
geneic and syngeneic BMT after less toxic, nonlethal (i.e. nonmyeloabla­
tive) conditioning regimens on established disease in DBA/1 (H-2q) mice. 
Methods We induced arthritis in normal DBA/1 (H-2q) mice by immu­
nization with type II collagen (CII) in complete Freund's adjuvans (CFA).
To allow engraftment, we made use of anti-CD40 ligand monoclonal anti­
body (one injection of 0.5 mg ip) and nonlethal total body irradiation (TBI) 
of 6.0 Gy before BMT with 1 .0 x 1 0e7 total BM cells from syngeneic 
DBA/1 (H-2q) mice or from fully MHC-mismatched allogeneic BALB/c 
(H-2d) mice. After treatment, mice were scored for clinical arthritis, and 
serum was taken to measure the amounts of CII-specific antibodies.
Results We were able to induce stable and long-term (>300  days) 
donor chimerism (>95% ) after transplantation with fully MHC-mis- 
matched total BM cells from allogeneic BALB/c (H-2d) mice using a 
nonmyeloablative conditioning regimen. After initial exarcebation of 
arthritis shortly after allogeneic BMT, due to a graft-versus-host 
(GvH)/host-versus-graft (HvG) response, mice receiving allogeneic BM 
cells showed a significant suppression of arthritis and CII-specific anti- S31
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Allogeneic BMT can suppress both clinical disease and pathogeneic 
antibodies. (a) Clinical disease over time. (b) Anti-type II collagen 
antibodies are decreased after treatment.
bodies. Syngeneic BMT was also effective in suppressing clinical 
disease, although no effects on CII-specific antibodies could be 
observed.
Conclusion These data indicate that nonmyeloablative conditioning 
using low-dose TBI and anti-CD40 ligand monoclonal antibody fol­
lowed by MHC mismatched allogeneic BMT results in donor 
chimerism, disappearence of pathogeneic autoantibodies and improve­
ment in disease activity.
Miscellaneous
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Cross-reaction between the major epitope of Ro60 
protein (pep216-232) and a homologous peptide of 
Coxsackievirus 3C protease
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Background Coxsackievirus RNA has recently been detected in 
biopsy specimens of minor salivary glands from patients with Sjogren's 
syndrome (SS). A peptide of 3C  protease of Coxsackievirus (pepCoxs) 
has 87%  homology with a major linear B-cell epitope of Ro60 protein 
spanning the sequence 216-232aa.
Objective To investigate a possible cross-reaction between Coxsack­
ievirus 3C protease and Ro60 autoantigen.
Methods PepCoxs MVTSTITEKLLKNLVKI and pep216-232 of Ro60 
KALSVETEKLLKYLEAV were prepared. Sera from 27 patients with SS 
and 28 patients with systemic lupus erythematosus (SLE) were tested 
against the two homologous peptides. Twenty-eight samples were a­
Ro (+), and 26 samples were a-Ro/a-La (+). Sera from 27 healthy indi­
viduals were used as normal controls. Antibodies against Ro60 peptide 
were purified and tested for antipeptide reactivity.
Results Of SLE sera 25%, and 33.3% of SS sera reacted against 
pep216-232, whereas 28% of SLE sera and 37% of SS sera reacted 
against pepCoxs. The reactivity of normal sera against pep216-232 
and pepCoxs was 17.4% and 3.7%, respectively. Pep21 6-232 was 
recognized by 17% of the a-Ro (+) sera and by 42% of the a-Ro/La (+) 
sera, whereas pepCoxs was recognized by 28.5% and 38% of the a­
Ro (+) and a-Ro/La (+) sera, respectively. Both peptides reacted more 
prominently with a-Ro/La (+) sera from SS patients. Purified a-Ro60 
antibodies reacted with both peptides and inhibition experiments 
revealed the specificity of this reaction.
Conclusion These results revealed a possible cross-reaction between 
the major linear B-cell epitope of Ro60 protein (216-232aa) and the 
homologous peptide of Coxsackie virus 3C-protease in SS patients. 
This cross-reaction might potentially play a role on autoantibody forma­
tion and pathogenesis of SS.
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rheumatoid arthritis
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Background HDJ2 is among approximately 98 human DnaJ homologues 
listed in protein databases. DnaJ homologues cooperate with HSP70 
chaperones, which regulate protein conformation under stress as well as 
normal physiological conditions. Functions of the HSP70 chaperone 
machinery include destruction and repair of misfolded proteins. We previ­
ously observed that several DnaJ homologs are differentially expressed in 
synovial tissue of patients with rheumatoid arthritis (RA).
Objective HDJ2 is one of the few DnaJ homologues that can be 
detected specifically as protein and mRNA. W e therefore wished to 
evaluate its expression on both levels in material derived from RA 
patients or healthy donors (HD).
Methods Synovial tissue (ST) from RA patients and appropriate con­
trols was stained with a specific monoclonal antibody (immunohisto- 
chemistry). The expression of HDJ2 was characterized in peripheral 
blood (PB) mononuclear cells (MNC) from HD; PBMNC from RA 
patients; and MNC from synovial fluid (SFMNC) and ST from RA 
patients. PB and SF leukocytes isolated by density gradient centrifuga­
tion were separated in monocytes (MC), remaining mononuclear cells 
(nonMC) and granulocytes. Cell populations were analyzed for HDJ2 
expression by FACS and RT-PCR.
Results HDJ2 mRNA was expressed in PBMNC of HD. Separation of 
PBMNC in MC and nonMC showed HDJ2 mRNA in both populations. 
HDJ2 protein was detected intracellularly in PBMNC of HD by FACS 
analysis, with stronger signals in MC than in nonMC. PBMNC derived 
from HD and RA patients did not show any surface expression of HDJ2. 
PB and SF leukocytes from RA patients varied in their HDJ2 mRNA 
expression between presence and absence. HDJ2 protein was overex­
pressed in RAST and detected on the cell surface of RA SFMNC. 
Conclusions HDJ2 mRNA and protein expression are regulated differ­
entially. More patients must be analyzed to describe possible correla­
tions between expression patterns and other parameters and to 
understand the function of synovial HDJ2 expression. 
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Background mPGES-1 catalyzes the formation of PGE2 from COX- 
derived PGH2. mPGES-1 is induced by proinflammatory cytokines and 
linked to conditions with high PGE2 biosynthesis. Recent studies in 
animals suggest that mPGES-1 upregulation is involved in the pathogen­
esis of inflammatory arthritis, and thus has important clinical relevance for 
a better understanding and treatment of rheumatoid arthritis (RA).
Available online http://arthritis-research.com/supplements/6/S1
Objective Our aim was to study the effects of different antirheumatic 
therapies on expression of mPGES-1 in RA synovial tissue.
Methods Synovial biopsies were taken by arthroscopy in patients with 
RA before and after TNF-blocking therapy with either etanercept (eight 
patients) or infliximab (10 patients), and in patients with chronic inflam­
matory arthritis before and after intra-articular injection of steroids 
(16 patients). Immunohistological analysis was performed using anti­
body against mPGES-1 and COX-2. Double immunofluorescence 
(DIF) was performed with antibodies to CD3, CD20, CD68, CD163 
and prolyne-4-hydroxylase.
Results mPGES-1 staining was detected in synovial lining cells, in sub­
lining scattered cells in all patients, and in endothelial cells in few 
patients. DIF showed that mPGES-1 is produced in synovial 
macrophages and fibroblasts, whereas in lymphocytes mPGES-1 expres­
sion was not observed. TNF-blocking therapy has heterogeneous effects 
on the expression of mPGES-1, as well as COX-2 in synovial tissues. 
Intra-articular steroid treatment significantly reduced both mPGES-1 and 
COX-2 expression in synovial tissues (P<  0.05); however, the downreg- 
ulation of mPGES-1 appears to be more prominent than that of COX-2. 
Conclusion The results demonstrate that corticosteroids but not TNF 
blockade downregulate mPGES-1. These data might be of importance 
for interpretation of effects of various therapies and provide support to 
the use of combination of TNF-blockade, corticosteroids, and nons­
teroidal anti-inflammatory drugs.
99
Salivary gland epithelial cells (SGEC) express a novel 
alternate transcript of the B7.2 costimulatory 
molecule that lacks the CD28/CTLA4-binding IgV-like 
domain
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Background Epithelial cells appear to have a central role in the patho­
genesis of Sjogren's syndrome (SS), by acting as antigen-presenting 
cells. SGEC lines established from minor SG biopsies of SS patients 
express MHC and B7 costimulatory molecules. We previously showed 
that B7.2 molecules expressed by SGEC display distinctive binding 
properties denoted by the functional interaction with CD28 receptor 
and reduced binding to the negative immune regulator CTLA4. 
Objective and Methods To delineate the role of RNA modifications in 
the SG EC-B7.2 protein binding properties, we applied a RT-PCR pro­
tocol that amplifies the entire coding region of the B7.2 mRNA. The 
amplified PCR products were sequenced and characterized.
Results SGEC were found to express three distinct alternate tran­
scripts of the B7.2 molecule. These included the two previously 
described transcripts (encoding the full-length and the soluble form, 
respectively), as well as a third novel form (designated as B7.2C). 
B7.2C is characterized by exon 4 deletion, which encodes the IgV-like 
binding domain of the B7.2 protein to the CD28 and CTLA4 receptors. 
The conservation of the signaling peptide and the transmembrane 
region in the B7.2C transcript suggests the membranous expression of 
the encoded protein. The cell surface expression of the B7.2C protein 
was verified in CHO cell lines transfected with this transcript. B7.2C 
mRNA analysis of peripheral blood cell subpopulations (monocytes, T 
and B cells) revealed exclusive expression by monocytes.
Conclusion The role of B7.2C transcript remains to be determined. 
The clustering of B7.2 molecules and the development of a network 
has been considered necessary for their effective interaction with 
CD28/CTLA4 receptors. Thus, the co-expression of the full length 
B7.2 with the truncated B7.2C protein (that lacks the CD28/CTLA4- 
binding sites) may lead to negative regulation of T cell activation by 
interference of B7.2C in the formation of B7.2 clusters.
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Background HMG-Co A reductase inhibitors (statins) are widely used 
lipid-lowering agents. It has recently been shown that, in addition to 
their well known effect on cholesterol levels, statins display anti-inflam­
matory activities both in vitro and in vivo. In this context, in vivo prophy­
lactic and therapeutic effects of simvastatin were recently described in 
mouse collagen-induced arthritis, a well-described experimental model 
for human rheumatoid arthritis (RA).
Objective and Methods The aim of this study was to investigate further 
the in vivo effects of three different statins -  atorvastatin, rosuvastatin and 
simvastatin -  using the same experimental model. Different doses and 
routes of administration were used for the various statins in an attempt to 
elicit antiarthritic activity in preventive and curative treatment protocols.
Results Atorvastatin and rosuvastatin had no in vivo efficacy, as indi­
cated by clinical, histological (synovial hyperplasia, exsudate and carti­
lage damage), immunological (anti-type II collagen IgG production and 
T lymphocyte proliferation) and biochemical (IL-6, serum amyloid A and 
glucocorticoid production) parameters of inflammation and autoimmu­
nity. The previously described antiarthritic effects of intraperitoneal sim­
vastatin administration were reproduced in our experiments, but could 
be accounted for by very severe side effects of the treatment leading to 
increased glucocorticoid levels.
Conclusions This work shows that statins do not have any effect in a 
murine model of arthritis; this is an unexpected observation, given the 
previously described therapeutic effect of statins in immune-mediated 
inflammatory diseases. It is still unclear whether statins might have a 
benefit in rheumatic diseases.
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Background Myeloid related protein (MRP)8 and MRP14 are released 
by early monocytes upon contact with activated endothelium and corre­
late with inflammation in rheumatoid arthritis (RA) and juvenile arthritis. 
Objective The aim of the study was to investigate serum 
MRP8/MRP14 as biomarker for inflammation in chronic arthritis.
Methods The study included 40 RA patients with active joint involve­
ment (S JC =14 , C R P = 2.4 mg/dl, ESR =  28 mm/hour); 30 SpA 
patients with peripheral synovitis (S JC =2, CRP =  2.2 mg/dl, 
ES R =21 mm/hour); 10 AS patients with exclusive axial involvement 
(SJC =  0, CRP =  3.1 mg/dl, ESR = 19 mm/hour); and 20 healthy con­
trols (HC). In 20 RA, 10 peripheral SpA and 10 axial AS patients, sera 
were also obtained after 6 weeks of infliximab therapy. Serum 
MRP8/MRP14 was measured by ELISA.
Results MRP8/MRP14 was increased in RA (1075 ng/ml; P <  0.001), 
peripheral SpA (815 ng/ml; P < 0 .001 ) and axial AS (710 ng/ml;
P <  0.001), as compared with HC (280 ng/ml). In patients with periph­
eral synovitis, MRP8/MRP14 correlated with CRP (RA, r = 0 .77 ,
P <  0.001; peripheral SpA, r = 0 .69 , P <  0.001) and ESR (RA, r =0 .70 ,
P  < 0 .00 1 ; peripheral SpA, r =0 .62 , P  =0 .001). MRP8/MRP14 
decreased after infliximab in RA (P <0 .001), peripheral SpA S33
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(P =  0.009) and axial AS (P =  0.01 2). Of 9/40 RA, 6/30 peripheral 
SpA and 1/10 axial AS patients with C R P < 1 mg/dl, only one periph­
eral SpA patient had increased MRP8/MRP14 (> mean MRP8/MRP14 
in H C + 2S D ). Of 17/40 RA, 12/30 peripheral SpA and 6 axial AS 
patients with ESR< 20 mm/hour, 3/17 RA, 6/12 peripheral SpA and 
3 /6  axial AS patients had raised MRP8/MRP14. Finally, we assessed 
the sensitivity to change after infliximab. In RA and peripheral SpA, 
changes in MRP8/MRP14 were not different from changes in CRP and 
ESR, whereas in axial AS changes in MRP8/MRP14 were less pro­
nounced than changes in ESR (P =  0.005).
Conclusion Raised MRP8/MRP14 levels, correlations with CRP and 
ESR, and decrease after infliximab confirm that serum MRP8/MRP14 
reflect inflammation. Further research is warranted to assess the added 
value of MRP8/MRP14 as compared with CRP and ESR.
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Background Joint damage in rheumatoid arthritis (RA) is caused by a 
tumor-like proliferation of synovial cells, which is accompanied by an 
increase in vasculature (angiogenesis) to support the metabolic 
requirements. Technological improvements such as three-dimensional 
(3D) power Doppler sonography have made possible the assessment 
of a whole blood vessel tree in a region of interest (ROI).
Objective Because 3D power Doppler sonography plays an important 
role in obstetrics and oncology for assessing the vascular system, we 
used it to visualize intra-articular synovial new blood vessel formation in 
painful and swollen joints of patients with RA.
Methods Inflamed wrist, knee or finger joints in 21 patients with active 
RA were investigated by ultrasound. Vascularity near and inside the 
joint capsule was visualized by power Doppler mode. The online 3D 
power Doppler function, provided by the ATL/HDI 5000 vascular soft­
ware, was used to generate a 3D image of the periarticular and intra- 
articular blood vessels.
Results In 21 patients with RA who showed power Doppler signals in 
2D mode, the 3D function revealed a blood vessel tree branching out 
from periarticular small blood vessels into the joint capsule. Until now it 
was possible to obtain good 3D imaging of synovial vasculature in the 
wrist (15 patients), knee (three patients), and finger joints (MCP II and 
PIP III) (three patients).
Conclusion This is the first report on 3D power Doppler imaging of syn­
ovial angiogenesis. In comparison with 2D power Doppler, 3D mode 
reveals more and very small blood vessels in connection with the whole 
blood vessel tree, and provides a new opportunity to study the architec­
ture and morphological structure of synovial vasculature in various joint 
disorders and under different conditions. Thus 3D power Doppler 
sonography may be used as an ‘in vivo' model to study the mechanisms 
between inflammation and angiogenesis in rheumatoid joint damage.
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Background Joint destruction in rheumatoid arthritis (RA) is caused by 
S34 hypervascularized pannus which invades cartilage and bone. Angio-
genesis is recognized as a key event in the formation and maintenance 
of the pannus, which is regulated by a delicate balance of angiogenesis 
inducers, including vascular endothelial growth factor (VEGF), and dif­
ferent angiostatic agents. Technological improvements such as high­
resolution ultrasound and power Doppler mode make the discrimination 
between periarticular and intra-articular blood flow possible.
Objective We used power Doppler sonography to visualize intra-articu- 
lar new blood vessel formation as a result of angiogenesis to evaluate a 
possible correlation with serum VEGF levels.
Methods Vascularity near and inside the wrist of 23 RA patients and 
12 healthy controls was visualized by power Doppler sonography. 
Microvascular doppler flow was localized to either inside or outside the joint 
capsule, and estimated according to a grading from 1 to 4. Serum levels of 
VEGF were measured using a standard quantitative sandwich ELISA. 
Results Power Doppler mode identified increased synovial microvas- 
cular blood flow inside the joint capsule in 20 RA patients (87%), in 
comparison with in none of the healthy controls (P <  0.0001). Although 
the median serum VEGF level in RA patients (853 pg/ml) was higher 
than in healthy controls (638 pg/ml), qualitative Doppler sonographic 
estimation of the intensity of intra-articular synovial blood flow did not 
correlate with the actual serum VEGF level of the same patient. 
Conclusion Power Doppler sonography is a reliable imaging modality 
to detect increased intra-articular synovial microvascular blood flow as 
a result of vasodilatation and new blood vessel formation (angiogene­
sis) in acute arthritis of RA patients. A correlation with elevated serum 
VEGF levels indicates this method as a helpful tool to study the role of 
blood vessels in the rheumatoid inflammatory process.
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Impaired clearance of apoptotic cell material has been implicated in the 
pathogenesis of systemic lupus erythematosus (SLE). We analyzed the 
phagocytotic potency of macrophages differentiated from CD34-positive 
stem cells derived from the peripheral blood from SLE patients and normal 
healthy donors (NHD), respectively. Furthermore, we examined the uptake 
of beads and dying cells by granulocytes of SLE patients and NHD.
We found that, in a subgroup of SLE patients, the proliferation and dif­
ferentiation patterns of the stem cells were different in comparison with 
NHD. Furthermore, in SLE patients a significantly reduced number of 
macrophages differentiated out of the stem cells. Additionally, the 
uptake capacity of some macrophages of SLE patients was reduced in 
comparison with NHD. Regarding the phagocytosis of albumin beads, 
polyglobuline beads, apoptotic and necrotic cells as well as degraded 
chromatin, we found that macrophages and/or granulocytes of some 
SLE patients showed a strongly reduced uptake of the prey.
The defective clearance of dying cells in a subgroup of SLE patients 
seems to be an intrinsic defect because fewer macrophages differenti­
ated out of stem cells, and some of the generated phagocytes also 
showed reduced uptake efficiency. Furthermore, the impaired clear­
ance capacities of granulocytes from some SLE patients could play an 
important role in the development of autoimmunity.
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Background Anti-SL (Ki) antibody was described in 1981 in patients 
affected by systemic lupus erythematosus (SLE) and sicca symptoms.
Available online http://arthritis-research.c0m/supplements/6/S I
Objective To evaluate clinical and serological profile associated with 
anti-SL antibodies
Methods Twenty-six consecutive sera with anti-Sl antibodies, selected 
from our laboratory routine ENA detection, were studied. All sera were 
analyzed by counter immunoelectrophoresis (CIE) for anti-ENA detec­
tion, using rabbit thymus and human spleen extract as substrates. ANA 
(by IFI assay on HEp-2 cells), anti-dsDNA (by Farr assay), anti-ENA, 
anticardiolipin (aCL) and anti-beta2GPI (by ELISA) were detected at 
disease onset and during follow up. The patients (20 female and 6 
male) had a mean age at onset of 39.4 years (SD: 18.3 years) and a 
mean follow-up of 10.7 years (SD: 7.3 years).
Results All the patients were affected by autoimmune rheumatic dis­
eases, but one with HCV-related cryoglobulinemia. SLE and primary 
Sjögren Syndrome (pSS) were the most frequent diagnoses achieved 
(in 13 and in 6 cases, respectively). Main clinical features were repre­
sented by skin involvement (65%), Raynaud's phenomenon (38%), 
xerophtalmia (54%), xerostomia (34%) and serositis (15%). Neverthe­
less, severe manifestations of disease were frequently observed: CNS 
involvement in three (11.5%) and renal disease in four cases (15%), 
while one patient with SLE had primary pulmonary hypertension. No 
cases of hemolytic anemia or severe cytopenia were recorded. ANA 
positivity was observed in all the sera. Anti-SL antibodies were 
detected as isolated antibody specificity in only five patients, while nine 
sera showed reactivity to anti-SL plus one antinuclear specificity (5 
anti-dsDNA, 2 anti-Ro, one anti-RNP, one anti-Sm). Ten patients had 
anti-SL antibodies associated with two other ANA specificities: in five 
cases, anti-Ro and anti-dsDNA; in three, anti-Ro and anti-La; in two 
cases, anti-Sm and anti-dsDNA. Two patients showed multiple antinu­
clear specificities (anti-SL with anti-Ro, anti-La and anti-dsDNA in one 
case and anti-SL with anti-Ro, anti-Ku and anti-dsDNA in another). Anti­
cardiolipin and anti-beta2GPI were detected in seven and four patients, 
respectively.
Conclusion Anti-SL antibodies identify a group of patients mainly 
affected by SLE and pSS, presenting in approximately one third of 
patients a severe disease with pulmonary, CNS or kidney involvement. 
Twenty-one patients with anti-SL (81%) have multiple antinuclear 
specificities.
between HSE and K4IM. MTX affected 191/1365, Decortin 84/172 
and Diclofenac 19/0 genes in HSE/K4IM, respectively, as identified by 
all three softwares in common. Only 41, 26, or 8 genes were influ­
enced in HSE towards the K4IM profile by MTX, Decortin or 
Diclofenac, respectively. Regulation of ten selected genes was con­
firmed by RT-PCR. Proteins in the supernatant from three of four genes 
revealed similar ratios by ELISA compared to transcription levels. 
Conclusion Only a minority of differentially regulated genes in the RA 
fibroblasts was positively influenced by current therapeutics. Those 
genes, which were not influenced, may be new potential candidates for 
therapeutic intervention.
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Background Rheumatoid arthritis (RA) synovial fibroblasts destruc­
tively invade into joint cartilage. We could demonstrate in our pannus 
model of interactive three-dimensional tissue culture that the immortal­
ized synovial fibroblast cells from a normal donor (K4IM) and a patient 
with RA (HSE) provide an in vitro system for differential invasiveness 
into artificial cartilage.
Objective In this study, we investigated the molecular differences 
between these two cell lines and the influence of antirheumatic drugs 
on their expression profiles to gain insight into molecular pathways of 
joint destruction.
Methods HSE and K4IM cells were characterized by immunostaining 
with Fibroblast-AK, CD3, CD31, CD68 and MAC3 antibodies. MTS- 
assay provided information for kinetics and effective concentration of 
MTX, decortin and diclofenac. Gene expression profiles were gener­
ated with HG-U133A Affymertrix GeneChips, analyzed by RMA, dCHIP 
and MAS5.0 software, and validated by RT-PCR, ELISA.
Results Positive fibroblast-AK staining confirmed the fibroblastoid phe­
notype of both cell lines. RA fibroblasts reacted more sensitively 
towards MTX-mediated cytotoxicity compared to K4IM fibroblasts. 
Gene expression profiling revealed 1303 differentially expressed genes S35
